Document:

Amended and Restated Executive Change in Control and Severance Benefit Plan

 Exhibit 10.34 
 JAZZ PHARMACEUTICALS PLC 
 AMENDED AND RESTATED 

EXECUTIVE CHANGE IN CONTROL AND SEVERANCE BENEFIT PLAN 

 

	SECTION 1.	INTRODUCTION. 

 The Jazz
Pharmaceuticals plc Amended and Restated Executive Change in Control and Severance Benefit Plan (the “Plan”) is hereby amended effective February 14, 2012 (originally established effective May 1, 2007 (the
“Effective Date”) and subsequently amended on February 17, 2009 and October 24, 2011). The purpose of the Plan is to provide for the payment of severance benefits to certain eligible executive employees of Jazz
Pharmaceuticals plc (the “Company”) or its Affiliates in the event that such employees are subject to qualifying employment terminations in connection with a Change in Control. This Plan shall supersede any individually
negotiated employment or severance benefit agreement and any generally applicable severance or change in control plan, policy, or practice, whether written or unwritten, with respect to each employee who becomes a Participant in the Plan, in each
case to the extent that such agreement, plan, policy or practice provides for benefits upon a Covered Termination (as defined herein). This Plan document also constitutes the Summary Plan Description for the Plan. 

 

	SECTION 2.	DEFINITIONS. 

 For
purposes of the Plan, the following terms are defined as follows: 
 (a) “Affiliate” means any
“parent” or “subsidiary” of the Company as such terms are defined in Rule 405 of the Securities Act of 1933, as amended. 
 (b) “Base Salary” means the Participant’s annual base pay (excluding incentive pay, premium pay, commissions, overtime, bonuses and other forms of variable
compensation), at the rate in effect during the last regularly scheduled payroll period immediately preceding the date of the Participant’s Covered Termination (without giving effect to any reduction in annual base pay after a Change in Control
that would constitute grounds for Constructive Termination); provided, however, that if the participant has, during the 12 months prior to the date of the Participant’s Covered Termination, taken a voluntary pay reduction, then the
annual base pay will be determined without regard to such voluntary reduction (assuming that the annual base pay did not include such voluntary reduction). 
 (c) “Board” means the Board of Directors of Jazz Pharmaceuticals plc. 
 (d) “Bonus Percentage” means the greater of (i) any annual bonus, as a percentage of annual base salary paid in the year of determination, paid to the Participant in
respect of either of the last two calendar years prior to the date of a Covered Termination or (ii) the Participant’s target bonus, expressed as a percentage of annual base salary, for the calendar year in which the Covered Termination
occurs; provided, however, that if the Participant was not employed for the entire calendar year prior to the date of a Covered Termination, the “Bonus Percentage” shall be 

  
 1. 

 
the greater of (x) the average bonus, as a percentage of annual base salary, for all similarly situated employees at the Company (e.g., all Vice Presidents, all Senior Vice
Presidents, etc.) who were employed for the entire calendar year prior to the date of a Covered Termination or (y) the Participant’s target bonus, expressed as a percentage of annual base salary, for the calendar year in which the Covered
Termination occurs. For purposes of the foregoing and this Plan, in the case of any Participant who is a Vice President, the Participant’s target bonus for the calendar year in which the Covered Termination occurs shall mean 30% of the
Participant’s annual base salary, notwithstanding any contrary provision set forth in any bonus or other plan maintained by the Company. 
 (e) “Bonus Multiplier” means the quotient obtained by dividing the number of full months that a Participant is employed in the year of a Covered Termination by twelve
(12). 
 (f) “Cause” means the occurrence of any one or more of the following: (i) the
Participant’s unauthorized use or disclosure of the confidential information or trade secrets of Company or its Affiliates which use or disclosure causes material harm to the Company or an Affiliate; (ii) the Participant’s material
breach of any agreement between the Participant and the Company or an Affiliate which remains uncured for ten (10) days after receiving written notification of the breach from the Board; (iii) the Participant’s material failure to
comply with the written policies or rules of the Company or an Affiliate which remains uncured for ten (10) days after receiving written notification of the breach from the Board; (iv) the Participant’s conviction of, or plea of
“guilty” or “no contest” to, any crime involving fraud, dishonesty, or moral turpitude under the laws of any United States Federal, state, local, or foreign governmental authority; (v) the Participant’s gross
misconduct; (vi) the Participant’s continuing failure to perform assigned duties after receiving written notification of the failure from the Board; or (vii) the Participant’s failure to cooperate in good faith with a
governmental or internal investigation of the Company, its Affiliates, directors, officers, or employees, if the Board has requested the Participant’s cooperation. 
 (g) “Change in Control” shall mean the occurrence, in a single transaction or in a series of related transactions, of any one or more of the following events: 

(i) any Exchange Act Person becomes the Owner, directly or indirectly, of securities of the Company representing more than fifty
percent (50%) of the combined voting power of the Company’s then outstanding securities other than by virtue of a merger, consolidation or similar transaction. Notwithstanding the foregoing, a Change in Control shall not be deemed to occur
(A) on account of the acquisition of securities of the Company by any institutional investor, any affiliate thereof or any other Exchange Act Person that acquires the Company’s securities in a transaction or series of related transactions
that are primarily a private financing transaction for the Company, a recapitalization of the Company or a conversion or restructuring of Company indebtedness or (B) solely because the level of Ownership held by any Exchange Act Person (the
“Subject Person”) exceeds the designated percentage threshold of the outstanding voting securities as a result of a repurchase or other acquisition of voting securities by the Company reducing the number of shares
outstanding, provided that if a Change in Control would occur (but for the operation of this sentence) as a result of the acquisition of voting securities by the Company, and after such share acquisition, the Subject Person becomes the Owner of any
additional voting securities that, assuming the repurchase or other acquisition had 

  
 2. 

 
not occurred, increases the percentage of the then outstanding voting securities Owned by the Subject Person over the designated percentage threshold, then a Change in Control shall be deemed to
occur; 
 (ii) there is consummated a merger, consolidation or similar transaction involving (directly or indirectly) the
Company if, immediately after the consummation of such merger, consolidation or similar transaction, the shareholders of the Company immediately prior thereto do not Own, directly or indirectly, either (A) outstanding voting securities
representing more than fifty percent (50%) of the combined outstanding voting power of the surviving Entity in such merger, consolidation or similar transaction or (B) more than fifty percent (50%) of the combined outstanding voting
power of the parent of the surviving Entity in such merger, consolidation or similar transaction, in either case, in substantially the same proportions as their ownership of the voting power of the Company’s securities immediately prior to such
merger, consolidation or similar transaction; 
 (iii) the shareholders of the Company approve or the Board approves a
plan of complete dissolution or liquidation of the Company, or a complete dissolution or liquidation of the Company shall otherwise occur; or 
 (iv) there is consummated a sale, lease, license or other disposition of all or substantially all of the consolidated assets of the Company and its Subsidiaries, other than a sale, lease, license
or other disposition of all or substantially all of the consolidated assets of the Company and its Subsidiaries to an Entity, more than fifty percent (50%) of the combined voting power of the voting securities of which are Owned by shareholders
of the Company in substantially the same proportion as their Ownership of the Company immediately prior to such sale, lease, license or other disposition. 
 For the avoidance of doubt, any one or more of the above events may be effected pursuant to (A) a compromise or arrangement sanctioned by the court under section 201 of the Companies Act 1963 of the
Republic of Ireland or (B) section 204 of the Companies Act 1963 of the Republic of Ireland. 
 Notwithstanding the
foregoing or any other provision of this Plan, the term Change in Control shall not include (1) a sale of assets, merger or other transaction effected exclusively for the purpose of changing the domicile of the Company or (2) unless the
Board determines otherwise, the creation of a new holding company where the Company becomes a wholly-owned subsidiary of that holding company and the holding company will be owned in substantially the same proportions by the persons who held the
Company’s issued shares immediately before such transaction. 
 (h) “COBRA” means the
Consolidated Omnibus Budget Reconciliation Act of 1985, as amended. 
 (i) “Code” means the
Internal Revenue Code of 1986, as amended. 
 (j) “Company” means Jazz Pharmaceuticals plc or,
following a Change in Control which is a sale of assets or a merger in which Jazz Pharmaceuticals plc is not the surviving entity, the entity to which the assets are sold or the surviving entity resulting from such transaction, respectively.

  
 3. 

 (k) “Constructive Termination” means a resignation of
employment by a Participant after an action or event which constitutes Good Reason is undertaken by the Company or an Affiliate, or occurs; provided, however, that in order for a Participant’s resignation to constitute a Constructive
Termination, such Participant must (i) provide written notice to the Company’s General Counsel within thirty (30) days after the first occurrence of the event giving rise to Good Reason setting forth the basis for such resignation,
(ii) allow the Company at least thirty (30) days from receipt of such written notice to cure such event, and (iii) if such event is not reasonably cured within such period, resign from all positions Participant then holds with the
Company and any Affiliate effective not later than ninety (90) days after the expiration of the cure period. 
 (l)
“Covered Termination” means either (i) an Involuntary Termination Without Cause, or (ii) a Constructive Termination, in each case within twelve (12) months following a Change in Control. Termination of
employment of a Participant due to death or disability shall not constitute a Covered Termination unless a resignation of employment by the Participant immediately prior to the Participant’s death or disability would have qualified as a
Constructive Termination. 
 (m) “Entity” means a corporation, partnership, limited liability
company, or other entity. 
 (n) “ERISA” means the Employee Retirement Income Security Act of
1974, as amended. 
 (o) “Exchange Act” means the Securities Exchange Act of 1934, as amended.

 (p) “Exchange Act Person” means any natural person, Entity or “group” (within the
meaning of Section 13(d) or 14(d) of the Exchange Act), except that “Exchange Act Person” shall not include (A) the Company or any Subsidiary of the Company; (B) any employee benefit plan of the Company or any Subsidiary of
the Company or any trustee or other fiduciary holding securities under an employee benefit plan of the Company or any Subsidiary of the Company; (C) an underwriter temporarily holding securities pursuant to an offering of such securities; or
(D) an Entity Owned, directly or indirectly, by the shareholders of the Company in substantially the same proportions as their Ownership of shares of the Company. 
 (q) “Involuntary Termination Without Cause” means a termination by the Company of a Participant’s employment relationship with the Company or an Affiliate for any
reason other than for Cause. 
 (r) “Good Reason” means the occurrence of any one or more of the
following actions or events: (i) a reduction in the Participant’s Base Salary by more than ten percent (10%) (other than a reduction in conjunction with (x) a Company-wide salary reduction, or (y) a salary reduction
involving senior management of the Company which results in salary reductions for employees similarly-situated to the Participant); (ii) a relocation of Participant’s place of employment by more than thirty-five (35) miles; provided
and only if such reduction or 

  
 4. 

 
relocation is effected without the Participant’s consent; (iii) a substantial reduction in the Participant’s duties or responsibilities (and not simply a change in reporting
relationships) in effect prior to the effective date of the Change in Control; provided, however, that it shall not constitute “Good Reason” if, following the effective date of the Change in Control, either (x) the Company is
retained as a separate legal entity or business unit and the Participant holds the same position in such legal entity or business unit as the Participant held before such effective date, or (y) the Participant holds a position with duties and
responsibilities comparable (though not necessarily identical, in view of the relative sizes of the Company and the entity involved in the Change in Control) to the duties and responsibilities of the Participant prior to the effective date of the
Change in Control; (iv) a reduction in the Participant’s title (e.g., the Participant no longer has a “Vice President” or “Senior Vice President”, etc. title); or (v) required travel by the Participant on
the Company’s business is substantially increased compared with the Participant’s business travel obligations prior to the Change in Control, provided and only if such increased business travel is effected without the Participant’s
consent. 
 (s) “Own,” “Owned,” “Owner,”
“Ownership” A person or Entity shall be deemed to “Own,” to have “Owned,” to be the “Owner” of, or to have acquired “Ownership” of securities if such person or Entity, directly or
indirectly, through any contract, arrangement, understanding, relationship or otherwise, has or shares voting power, which includes the power to vote or to direct the voting, with respect to such securities. 

(t) “Participant” means an individual who has been designated a Participant by the Plan Administrator in
its sole discretion (either by a specific designation or by virtue of being a member of a class of employees who have been so designated). 
 (u) “Plan Administrator” means the Board or any committee duly authorized by the Board to administer the Plan. The Plan Administrator may, but is not required to be, the
Compensation Committee of the Board. The Board may at any time administer the Plan, in whole or in part, notwithstanding that the Board has previously appointed a committee to act as the Plan Administrator. 

(v) “Subsidiary” shall mean any corporation (other than the Company) in an unbroken chain of corporations
beginning with the Company, if each of the corporations other than the last corporation in the unbroken chain owns stock possessing fifty percent (50%) or more of the total combined voting power of all classes of stock in one of the other
corporations in such chain. A corporation that attains the status of a Subsidiary on a date after the adoption of the Plan shall be considered a Subsidiary commencing as of such date. 

 

	SECTION 3.	ELIGIBILITY FOR BENEFITS. 

(a) General Rules. Subject to the limitations set forth in this Section 3, Section 5 and Section 6, in the event of
a Covered Termination, the Company shall provide the severance benefits described in Section 4 to each affected Participant. 
 (b) Exceptions to Benefit Entitlement. A Participant will not receive benefits under the Plan (or will receive reduced benefits under the Plan) in the following circumstances, as determined by the
Plan Administrator in its sole discretion: 
 (i) The Participant has executed an individually negotiated employment
contract or agreement with the Company relating to severance benefits that is in effect on his or her termination date and which provides for such benefits upon a Covered Termination. 

  
 5. 

 (ii) The Participant is entitled to receive benefits under another severance benefit
plan maintained by the Company on his or her termination date and which provides such benefits upon a Covered Termination. 

(iii) The Participant’s employment terminates or is terminated for any reason other than a Covered Termination. 

(iv) The Participant voluntarily terminates employment with the Company in order to accept employment with another entity that is
controlled (directly or indirectly) by the Company or is otherwise an Affiliate. 
 (v) The Participant does not confirm
in writing that he or she shall be subject to the Company’s Employee Confidential Information and Inventions Agreement. 
 (vi) The Participant is rehired prior to the date benefits under the Plan are scheduled to commence by the Company or an Affiliate for an identical or substantially equivalent or comparable
position as the Participant’s last position with the Company or an Affiliate. 
 (vii) The Participant is offered an
identical or substantially equivalent or comparable position with the Company, an Affiliate, or a successor pursuant to a Change in Control. For purposes of the foregoing, a “substantially equivalent or comparable position” is one that
offers the Participant substantially the same level of responsibility and Base Salary; provided, however, that a Participant shall not be considered to be offered a “substantially equivalent or comparable position” if a resignation
by the Participant would constitute Constructive Termination. 
 (viii) The Participant has failed to execute or has
revoked the release described in Section 5(a). 
 (c) Termination of Benefits. A Participant’s right to receive
benefits under this Plan shall terminate immediately if, at any time prior to or during the period for which the Participant is receiving benefits hereunder, the Participant, without the prior written approval of the Plan Administrator: 

(i) willfully breaches a material provision of the Company’s Employee Confidential Information and Inventions
Agreement; 
 (ii) encourages or solicits any of the Company’s then current employees to leave the
Company’s employ for any reason or interferes in any other manner with employment relationships at the time existing between the Company and its then current employees; or 

(iii) induces any of the Company’s then current clients, customers, suppliers, vendors, distributors, licensors, licensees or
other third party to terminate their existing business 

  
 6. 

 
relationship with the Company or interferes in any other manner with any existing business relationship between the Company and any then current client, customer, supplier, vendor, distributor,
licensor, licensee or other third party. 
  

	SECTION 4.	AMOUNT OF BENEFITS. 

 In
the event of a Participant’s Covered Termination, the Participant shall be entitled to receive the benefits provided by this Section 4. 
 (a) Cash Severance Benefits. The Company shall make a cash severance payment to the Participant in an amount equal to the sum of (i) the Participant’s Base Salary multiplied by the
percentage set forth below that applies to the Participant plus (ii) the product of (A) the Participant’s Base Salary, and (B) the Participant’s Bonus Percentage, and (C) the percentage set forth below that applies to
the Participant plus (iii) the product of (1) the Participant’s Base Salary and (2) the Participant’s Bonus Percentage and (3) the Participant’s Bonus Multiplier. 

 

					
	 If the Participant is at the time of the Covered Termination a:
	  	Applicable
Percentage:	 
	 Vice President
	  	 	100	% 
	 Senior Vice President and above (but not Chief Executive Officer, Executive Chairman or President)
	  	 	150	% 
	 Chief Executive Officer, Executive Chairman or President
	  	 	200	% 

 Such severance payment shall be paid in accordance with Section 6. 

(b) Health Continuation Coverage. 
 (i) Provided that the Participant is eligible for, and has made an election at the time of the Covered Termination pursuant to COBRA under a health, dental, or vision plan sponsored by the Company,
each such Participant shall be entitled to payment by the Company of all of the applicable premiums (inclusive of premiums for the Participant’s dependents for such health, dental, or vision plan coverage as in effect immediately prior to the
date of the Covered Termination) for such health, dental, or vision plan coverage for a period of twelve (12) months in the case of a Vice President, eighteen (18) months in the case of a Senior Vice President and above (but not the Chief
Executive Officer, Executive Chairman or President), and twenty-four (24) months in the case of the Chief Executive Officer, Executive Chairman or President, following the date of the Covered Termination, with such coverage counted as coverage
pursuant to COBRA. 
 (ii) No such premium payments (or any other payments for health, dental, or vision coverage by the
Company) shall be made following the Participant’s death or the effective date of the Participant’s coverage by a health, dental, or vision insurance plan of a subsequent employer. Each Participant shall be required to notify the Plan
Administrator immediately if the Participant becomes covered by a health, dental, or vision insurance plan of a subsequent employer. Upon the conclusion of such period of insurance premium payments made by the Company, the Participant will be
responsible for the entire payment of premiums required under COBRA for the duration of the COBRA period. 

  
 7. 

 (iii) For purposes of this Section 4(b), (i) references to COBRA shall be
deemed to refer also to analogous provisions of state law, and (ii) any applicable insurance premiums that are paid by the Company shall not include any amounts payable by the Participant under an Internal Revenue Code Section 125 health
care reimbursement plan, which amounts, if any, are the sole responsibility of the Participant. 
 (iv) Notwithstanding
the foregoing, if at any time the Plan Administrator determines, in its sole discretion, that its payment of COBRA premiums on Participant’s behalf would result in a violation of applicable law (including, without limitation, Section 2716
of the Public Health Service Act), then in lieu of paying COBRA premiums pursuant to this Section 4(b), the Company will pay to Participant on the last day of each remaining month of the period of insurance premium payments which would
otherwise be made by the Company, a fully taxable cash payment equal to the COBRA premium for such month, subject to applicable tax withholding (such amount, the “Special Severance Payment”), such Special Severance Payment to
be made without regard to Participant’s payment of COBRA premiums and without regard to the expiration of the COBRA period prior to the twelve (12), eighteen (18) or twenty-four (24) months, as applicable, following the date of the
Covered Termination. Such Special Severance Payment shall end on the earlier of (x) the date on which Participant commences other employment and (y) the close of the twelve (12), eighteen (18) or twenty-four (24)-month
period, as applicable, following the date of the Covered Termination. 
 (v) The Company will make
the first COBRA premium or the Special Severance Payment, if applicable in a lump sum on the sixtieth (60th) day following a Participant’s Covered Termination, in an amount equal to the aggregate amount of payments that the Company would have paid through such date had such payments commenced on the
Covered Termination through such sixtieth (60th) day,
with the balance of the payments paid thereafter on the schedule described above. 
 (c) Stock Award Vesting
Acceleration. Upon a Covered Termination, (i) the vesting and exercisability of all outstanding options to purchase the Company’s ordinary shares (or stock appreciation rights or similar rights or other rights with respect to
shares of the Company issued pursuant to any equity incentive plan of the Company) that are held by the Participant on such date shall be accelerated in full, and (ii) any reacquisition or repurchase rights held by the Company with respect to
ordinary shares issued or issuable (or with respect to similar rights or other rights with respect to shares of the Company issued or issuable pursuant to any equity incentive plan of the Company) pursuant to any other stock award granted to the
Participant by the Company shall lapse. 
 (d) Other Employee Benefits. All other benefits (such as life insurance,
disability coverage, and 401(k) plan coverage) shall terminate as of the Participant’s termination date (except to the extent that a conversion privilege may be available thereunder). 

(e) Additional Benefits. Notwithstanding the foregoing, the Plan Administrator may, in its sole discretion, provide benefits in
addition to those pursuant to Sections 4(a), 4(b), 

  
 8. 

 
and 4(c) to one or more Participants chosen by the Plan Administrator, in its sole discretion, and the provision of any such benefits to a Participant shall in no way obligate the Company to
provide such benefits to any other Participant, even if similarly situated. 
  

	SECTION 5.	LIMITATIONS ON BENEFITS. 

(a) Release. In order to be eligible to receive benefits under the Plan, a Participant must execute a general waiver and release in
substantially the form attached hereto as EXHIBIT A, EXHIBIT B, or EXHIBIT C, as appropriate, and return to the Company, within the applicable time period set forth therein but in no event more than forty-five
(45) days following the date of the Participant’s Covered Termination and permit such release to become effective in accordance with its terms. Notwithstanding the foregoing, no such release shall require the Participant to forego any
unpaid salary, any accrued but unpaid vacation pay or any benefits payable pursuant to this Plan. With respect to any outstanding option held by the Participant, no provision set forth in this Plan granting the Participant additional rights to
exercise the option can be exercised unless and until the release becomes effective. Unless a Change in Control has occurred, the Plan Administrator, in its sole discretion, may modify the form of the required release to comply with applicable law
and shall determine the form of the required release, which may be incorporated into a termination agreement or other agreement with the Participant. 
 (b) Certain Reductions. The Plan Administrator, in its sole discretion, shall have the authority to reduce a Participant’s severance benefits, in whole or in part, by any other severance
benefits, pay in lieu of notice, or other similar benefits payable to the Participant by the Company that become payable in connection with the Participant’s termination of employment pursuant to (i) any applicable legal requirement,
including, without limitation, the Worker Adjustment and Retraining Notification Act (the “WARN Act”) or (ii) any Company policy or practice providing for the Participant to remain on the payroll for a limited period of
time after being given notice of the termination of the Participant’s employment. The benefits provided under this Plan are intended to satisfy, in whole or in part, any and all statutory obligations and other contractual obligations of the
Company, including benefits provided by offer letter or employment agreements, that may arise out of a Participant’s termination of employment, and the Plan Administrator shall so construe and implement the terms of the Plan. The Plan
Administrator’s decision to apply such reductions to the severance benefits of one Participant and the amount of such reductions shall in no way obligate the Plan Administrator to apply the same reductions in the same amounts to the severance
benefits of any other Participant, even if similarly situated. In the Plan Administrator’s sole discretion, such reductions may be applied on a retroactive basis, with severance benefits previously paid being re-characterized as payments
pursuant to the Company’s statutory or other contractual obligations. 
 (c) Parachute Payments. Except as otherwise
provided in an agreement between a Participant and the Company, if any payment or benefit the Participant would receive in connection with a Change in Control from the Company or otherwise (“Payment”) would
(i) constitute a “parachute payment” within the meaning of Section 280G of the Code, and (ii) but for this sentence, be subject to the excise tax imposed by Section 4999 of the Code (the “Excise
Tax”), then such Payment shall be equal to the Reduced Amount. The “Reduced Amount” shall be either (x) the largest portion of the Payment that would result in no portion of

  
 9. 

 
the Payment being subject to the Excise Tax, or (y) the largest portion, up to and including the total, of the Payment, whichever amount, after taking into account all applicable federal,
state and local employment taxes, income taxes, and the Excise Tax (all computed at the highest applicable marginal rate), results in the Participant’s receipt, on an after-tax basis, of the greater amount of the Payment notwithstanding that
all or some portion of the Payment may be subject to the Excise Tax. If a reduction in payments or benefits constituting “parachute payments” is necessary so that the Payment equals the Reduced Amount, reduction shall occur in the manner
that results in the greatest economic benefit for Participant. 
 (d) Mitigation. Except as otherwise specifically
provided herein, a Participant shall not be required to mitigate damages or the amount of any payment provided under this Plan by seeking other employment or otherwise, nor shall the amount of any payment provided for under this Plan be reduced by
any compensation earned by a Participant as a result of employment by another employer or any retirement benefits received by such Participant after the date of the Participant’s termination of employment with the Company, except for health
continuation coverage provided pursuant to Section 4(b). 
 (e) Non-Duplication of Benefits. Except as otherwise
specifically provided for herein, no Participant is eligible to receive benefits under this Plan or pursuant to other contractual obligations more than one time. This Plan is designed to provide certain severance pay and change in control benefits
to Participants pursuant to the terms and conditions set forth in this Plan. The payments pursuant to this Plan are in addition to, and not in lieu of, any unpaid salary, bonuses or benefits to which a Participant may be entitled for the period
ending with the Participant’s Covered Termination. 
  

	SECTION 6.	TIME OF PAYMENT AND FORM OF BENEFITS. 

 (a) General Rules. Except as otherwise set forth in the Plan, the cash severance benefits under Section 4(a) of the Plan, if any, shall be paid in a single lump sum payment on the
60th day following the Participant’s Covered
Termination. In no event shall payment of any Plan benefit set forth in Section 4 be made unless prior to such
60th day following a Participant’s Covered
Termination (i) such Participant has a “separation from service” (as defined under Treasury Regulation Section 1.409A-1(h), without regard to any alternative definition thereunder, a “Separation from
Service”) and (ii) such Participant has returned and allowed to become effective the release described in Section 5(a). For the avoidance of doubt, in the event of an acceleration of the exercisability of an option (or other
award) pursuant to Section 4(c), such option (or other award) shall not be exercisable with respect to such acceleration of exercisability unless and until the 60th day following the Participant’s Covered Termination. 

(b) Application of Section 409A. It is intended that all of the severance benefits payable under this Plan satisfy, to the
greatest extent possible, the exemptions from the application of Section 409A of the Code and the regulations and other guidance thereunder and any state law of similar effect (collectively, “Section 409A”) provided
under Treasury Regulations 1.409A-1(b)(4), 1.409A-1(b)(5) and 1.409A-1(b)(9), and that this Plan will be construed to the greatest extent possible as consistent with those provisions, and to the extent no so exempt, this Plan (and any definitions
hereunder) will be construed in a manner that complies with Section 409A. For purposes of Section 409A (including, without limitation, for purposes of 

  
 10.

 
Treasury Regulation Section 1.409A-2(b)(2)(iii)), a Participant’s right to receive any installment payments under this Plan (whether severance payments, reimbursements or otherwise)
shall be treated as a right to receive a series of separate payments and, accordingly, each installment payment hereunder shall at all times be considered a separate and distinct payment. Severance benefits shall not commence until a Participant has
a Separation from Service. Notwithstanding anything to the contrary herein, if the Plan Administrator determines that a Participant is, upon Separation from Service, a “specified employee” for purposes of Section 409A, then, solely to
the extent necessary to avoid adverse personal tax consequences under Section 409A, the timing of any severance benefits shall be delayed until the earlier of (i) six (6) months and one day after Participant’s Separation from
Service (or such longer period as is required under applicable law, regulations or guidance under Section 409A), or (ii) Participant’s death. None of the severance benefits payable under this Plan will be paid or otherwise delivered
prior to the effective date of the release, which must occur on or prior to the 60th day following a Participant’s Separation from Service. Except to the minimum extent that payments must be delayed because Participant is a “specified employee”, all amounts will be paid as
soon as practicable in accordance with the terms of this Plan and the Company’s normal payroll practices. 
 (c) Tax
Withholding. All payments under the Plan will be subject to all applicable withholding of the Company, including, without limitation, obligations to withhold for federal, state and local income and employment taxes. 

(d) Indebtedness of Participants. If a Participant is indebted to the Company on the effective date of his or her Covered
Termination, the Plan Administrator reserves the right to offset any severance payments under the Plan by the amount of such indebtedness. 
  

	SECTION 7.	RIGHT TO INTERPRET PLAN; AMENDMENT AND TERMINATION. 

 (a) Exclusive Discretion. The Plan Administrator shall have the exclusive discretion and authority to establish rules, forms, and procedures for the administration of the Plan, and to construe and
interpret the Plan and to decide any and all questions of fact, interpretation, definition, computation or administration arising in connection with the operation of the Plan, including, but not limited to, the eligibility to participate in the Plan
and amount of benefits paid under the Plan. The rules, interpretations, computations and other actions of the Plan Administrator shall be binding and conclusive on all persons. 

(b) Amendment or Termination. The Company reserves the right to amend or terminate this Plan, or the benefits provided hereunder
at any time; provided, however, that no such amendment or termination shall occur following a Change in Control or a Covered Termination as to any Participant who would be adversely affected by such amendment or termination unless such
Participant consents in writing to such amendment or termination. Any action amending or terminating the Plan shall be in writing and executed by a duly authorized officer of the Company. 

  
 11.

	SECTION 8.	NO IMPLIED EMPLOYMENT CONTRACT. 

 The Plan shall not be deemed (i) to give any employee or other person any right to be retained in the employ of the Company or an Affiliate, or (ii) to interfere with the right of the Company or
an Affiliate to discharge any employee or other person at any time, with or without cause, which right is hereby reserved. 
  

	SECTION 9.	LEGAL CONSTRUCTION. 

 This
Plan is intended to be governed by and shall be construed in accordance with ERISA and, to the extent not preempted by ERISA, the laws of the State of California. 
  

	SECTION 10.	CLAIMS, INQUIRIES AND APPEALS. 

 (a) Applications for Benefits and Inquiries. Any application for benefits, inquiries about the Plan or inquiries about present or future rights under the Plan must be submitted to the Plan
Administrator in writing by an applicant (or his or her authorized representative). The Plan Administrator is set forth in Section 12(d). 
 (b) Denial of Claims. In the event that any application for benefits is denied in whole or in part, the Plan Administrator must provide the applicant with written or electronic notice of the
denial of the application, and of the applicant’s right to review the denial. Any electronic notice will comply with the regulations of the U.S. Department of Labor. The notice of denial will be set forth in a manner designed to be understood
by the applicant and will include the following: 
 (i) the specific reason or reasons for the denial; 

(ii) references to the specific Plan provisions upon which the denial is based; 

(iii) a description of any additional information or material that the Plan Administrator needs to complete the review and an
explanation of why such information or material is necessary; and 
 (iv) an explanation of the Plan’s review
procedures and the time limits applicable to such procedures, including a statement of the applicant’s right to bring a civil action under Section 502(a) of ERISA following a denial on review of the claim, as described in
Section 10(d) below. 
 This notice of denial will be given to the applicant within ninety (90) days after the Plan
Administrator receives the application, unless special circumstances require an extension of time, in which case, the Plan Administrator has up to an additional ninety (90) days for processing the application. If an extension of time for
processing is required, written notice of the extension will be furnished to the applicant before the end of the initial ninety (90) day period. 
 This notice of extension will describe the special circumstances necessitating the additional time and the date by which the Plan Administrator is to render its decision on the application. 

  
 12.

 (c) Request for a Review. Any person (or that person’s authorized
representative) for whom an application for benefits is denied, in whole or in part, may appeal the denial by submitting a request for a review to the Plan Administrator within sixty (60) days after the application is denied. A request for a
review shall be in writing and shall be addressed to: 
 Jazz Pharmaceuticals plc 

Attn: General Counsel 
 c/o Jazz Pharmaceuticals, Inc. 
 3180 Porter Drive 

Palo Alto, CA 94304 
 A request for review must set forth all of the grounds on which it is based, all facts in support of the request and any other matters that the applicant feels are pertinent. The applicant (or his or her
representative) shall have the opportunity to submit (or the Plan Administrator may require the applicant to submit) written comments, documents, records, and other information relating to his or her claim. The applicant (or his or her
representative) shall be provided, upon request and free of charge, reasonable access to, and copies of, all documents, records and other information relevant to his or her claim. The review shall take into account all comments, documents, records
and other information submitted by the applicant (or his or her representative) relating to the claim, without regard to whether such information was submitted or considered in the initial benefit determination. 

(d) Decision on Review. The Plan Administrator will act on each request for review within sixty (60) days after
receipt of the request, unless special circumstances require an extension of time (not to exceed an additional sixty (60) days), for processing the request for a review. If an extension for review is required, written notice of the extension
will be furnished to the applicant within the initial sixty (60) day period. This notice of extension will describe the special circumstances necessitating the additional time and the date by which the Plan Administrator is to render its
decision on the review. The Plan Administrator will give prompt, written or electronic notice of its decision to the applicant. Any electronic notice will comply with the regulations of the U.S. Department of Labor. In the event that the Plan
Administrator confirms the denial of the application for benefits in whole or in part, the notice will set forth, in a manner calculated to be understood by the applicant, the following: 

(i) the specific reason or reasons for the denial; 
 (ii) references to the specific Plan provisions upon which the denial is based; 
 (iii) a statement that the applicant is entitled to receive, upon request and free of charge, reasonable access to, and copies of, all documents, records and other information relevant to his or
her claim; and 
 (iv) a statement of the applicant’s right to bring a civil action under Section 502(a) of
ERISA. 
 (e) Rules and Procedures. The Plan Administrator will establish rules and procedures, consistent with the Plan
and with ERISA, as necessary and appropriate in carrying out its responsibilities in reviewing benefit claims. The Plan Administrator may require an applicant who wishes to submit additional information in connection with an appeal from the denial
of benefits to do so at the applicant’s own expense. 

  
 13.

 (f) Exhaustion of Remedies. No legal action for benefits under the Plan may be
brought until the applicant (i) has submitted a written application for benefits in accordance with the procedures described by Section 10(a) above, (ii) has been notified by the Plan Administrator that the application is denied,
(iii) has filed a written request for a review of the application in accordance with the appeal procedure described in Section 10(c) above, and (iv) has been notified that the Plan Administrator has denied the appeal. Notwithstanding
the foregoing, if the Plan Administrator does not respond to an applicant’s claim or appeal within the relevant time limits specified in this Section 10, the applicant may bring legal action for benefits under the Plan pursuant to
Section 502(a) of ERISA. 
  

	SECTION 11.	BASIS OF PAYMENTS TO AND FROM PLAN. 

 The Plan shall be unfunded, and all benefits hereunder shall be paid only from the general assets of the Company. 
  

	SECTION 12.	OTHER PLAN INFORMATION. 

(a) Employer and Plan Identification Numbers. The Employer Identification Number assigned to the Company (which is the “Plan
Sponsor” as that term is used in ERISA) by the Internal Revenue Service is 98-1032470. The Plan Number assigned to the Plan by the Plan Sponsor pursuant to the instructions of the Internal Revenue Service is 502. 

(b) Ending Date for Plan’s Fiscal Year. The date of the end of the fiscal year for the purpose of maintaining the Plan’s
records is December 31. 
 (c) Agent for the Service of Legal Process. The agent for the service of legal process
with respect to the Plan is: 
 Jazz Pharmaceuticals plc 
 Attn: General Counsel 
 c/o Jazz Pharmaceuticals, Inc. 

3180 Porter Drive 

Palo Alto, CA 94304 
 (d) Plan Sponsor and Administrator. The “Plan Sponsor” of the Plan is: 
 Jazz Pharmaceuticals plc 
 Attn: General Counsel 

c/o Jazz Pharmaceuticals, Inc. 
 3180 Porter Drive 
 Palo Alto, CA 94304 

The “Plan Administrator” of the Plan is as set forth in Section 2(u). The Plan Sponsor’s and Plan Administrator’s telephone
number is (650) 496-3777. The Plan Administrator is the named fiduciary charged with the responsibility for administering the Plan. 

  
 14.

	SECTION 13.	STATEMENT OF ERISA RIGHTS. 

Participants in this Plan (which is a welfare benefit plan sponsored by Jazz Pharmaceuticals plc) are entitled to certain rights and
protections under ERISA. If you are a Participant, you are considered a participant in the Plan for the purposes of this Section 13 and, under ERISA, you are entitled to: 
 (a) Receive Information About Your Plan and Benefits 
 (i) Examine,
without charge, at the Plan Administrator’s office and at other specified locations, such as worksites, all documents governing the Plan and a copy of the latest annual report (Form 5500 Series), if applicable, filed by the Plan with the U.S.
Department of Labor and available at the Public Disclosure Room of the Employee Benefits Security Administration; 
 (ii)
Obtain, upon written request to the Plan Administrator, copies of documents governing the operation of the Plan and copies of the latest annual report (Form 5500 Series), if applicable, and an updated (as necessary) Summary Plan Description. The
Plan Administrator may make a reasonable charge for the copies; and 
 (iii) Receive a summary of the Plan’s annual
financial report, if applicable. The Plan Administrator is required by law to furnish each participant with a copy of this summary annual report. 
 (b) Prudent Actions By Plan Fiduciaries. In addition to creating rights for Plan participants, ERISA imposes duties upon the people who are responsible for the operation of the employee benefit
plan. The people who operate the Plan, called “fiduciaries” of the Plan, have a duty to do so prudently and in the interest of you and other Plan participants and beneficiaries. No one, including your employer, your union or any other
person, may fire you or otherwise discriminate against you in any way to prevent you from obtaining a Plan benefit or exercising your rights under ERISA. 
 (c) Enforce Your Rights. 
 (i) If your claim for a Plan benefit is
denied or ignored, in whole or in part, you have a right to know why this was done, to obtain copies of documents relating to the decision without charge, and to appeal any denial, all within certain time schedules. 

(ii) Under ERISA, there are steps you can take to enforce the above rights. For instance, if you request a copy of Plan documents
or the latest annual report from the Plan, if applicable, and do not receive them within 30 days, you may file suit in a Federal court. In such a case, the court may require the Plan Administrator to provide the materials and pay you up to $110 a
day until you receive the materials, unless the materials were not sent because of reasons beyond the control of the Plan Administrator. 
 (iii) If you have a claim for benefits which is denied or ignored, in whole or in part, you may file suit in a state or Federal court. 

  
 15.

 (iv) If you are discriminated against for asserting your rights, you may seek
assistance from the U.S. Department of Labor, or you may file suit in a Federal court. The court will decide who should pay court costs and legal fees. If you are successful, the court may order the person you have sued to pay these costs and fees.
If you lose, the court may order you to pay these costs and fees, for example, if it finds your claim is frivolous. 
 (d)
Assistance With Your Questions. If you have any questions about the Plan, you should contact the Plan Administrator. If you have any questions about this statement or about your rights under ERISA, or if you need assistance in obtaining
documents from the Plan Administrator, you should contact the nearest office of the Employee Benefits Security Administration, U.S. Department of Labor, listed in your telephone directory or the Division of Technical Assistance and Inquiries,
Employee Benefits Security Administration, U.S. Department of Labor, 200 Constitution Avenue N.W., Washington, D.C. 20210. You may also obtain certain publications about your rights and responsibilities under ERISA by calling the publications
hotline of the Employee Benefits Security Administration. 
  

	SECTION 14.	GENERAL PROVISIONS. 

(a) Notices. Any notice, demand or request required or permitted to be given by either the Company or a Participant pursuant to the
terms of this Plan shall be in writing and shall be deemed given when delivered personally or deposited in the U.S. mail, First Class with postage prepaid, and addressed to the parties, in the case of the Company, at the address set forth in
Section 12(d) and, in the case of a Participant, at the address as set forth in the Company’s employment file maintained for the Participant as previously furnished by the Participant or such other address as a party may request by
notifying the other in writing. 
 (b) Transfer and Assignment. The rights and obligations of a Participant under this
Plan may not be transferred or assigned without the prior written consent of the Company. This Plan shall be binding upon any surviving entity resulting from a Change in Control and upon any other person who is a successor by merger, acquisition,
consolidation or otherwise to the business formerly carried on by the Company without regard to whether or not such person or entity actively assumes the obligations hereunder. 

(c) Waiver. Any Party’s failure to enforce any provision or provisions of this Plan shall not in any way be construed as a
waiver of any such provision or provisions, nor prevent any Party from thereafter enforcing each and every other provision of this Plan. The rights granted the Parties herein are cumulative and shall not constitute a waiver of any Party’s right
to assert all other legal remedies available to it under the circumstances. 
 (d) Severability. Should any provision of
this Plan be declared or determined to be invalid, illegal or unenforceable, the validity, legality and enforceability of the remaining provisions shall not in any way be affected or impaired. 

(e) Section Headings. Section headings in this Plan are included for convenience of reference only and shall not be considered
part of this Plan for any other purpose. 

  
 16.

	SECTION 15.	EXECUTION. 

 To record the
adoption of the Plan as set forth herein as of the Effective Date, the assumption of the Plan by Jazz Pharmaceuticals plc as of January 18, 2012, and the amendment and restatement of the Plan, Jazz Pharmaceuticals plc has caused its duly
authorized officer to execute the same as of April 24, 2012. 
  

			
	JAZZ PHARMACEUTICALS PLC
		
	By:	 	 /s/ Suzanne Sawochka Hooper

	Title:	 	Executive Vice President & General Counsel

 The Executive Change in Control and Severance Benefit Plan was effective on May 1, 2007. 

The Executive Change in Control and Severance Benefit Plan was amended and restated by the Board of Directors of Jazz Pharmaceuticals, Inc. on
February 17, 2009. 
 The Executive Change in Control and Severance Benefit Plan was amended and restated by the Board of Directors of Jazz
Pharmaceuticals, Inc. on October 24, 2011. 
 The Amended and Restated Executive Change in Control and Severance Benefit Plan was assumed
by Jazz Pharmaceuticals plc effective as of January 18, 2012. 
 The Amended and Restated Executive Change in Control and Severance Benefit
Plan was amended and restated by the Compensation Committee of the Board of Directors of Jazz Pharmaceuticals plc on February 14, 2012. 

The Amended and Restated Executive Change in Control and Severance Benefit Plan was amended and restated by the Compensation Committee of the Board of
Directors of Jazz Pharmaceuticals plc on April 24, 2012. 

  
 17.

 For Employees Age 40 or Older 

Individual Termination 
 EXHIBIT A 
 RELEASE AGREEMENT (“RELEASE”)

 I understand and agree completely to the terms set forth in the Jazz Pharmaceuticals plc Amended and Restated Executive Change in
Control and Severance Benefit Plan (the “Plan”). 
 I understand that this Release, together with the Plan,
constitutes the complete, final and exclusive embodiment of the entire agreement between the Company and me with regard to the subject matter hereof. I am not relying on any promise or representation by the Company that is not expressly stated
therein. Certain capitalized terms used in this Release are defined in the Plan. 
 I hereby confirm my obligations under my Employee
Confidential Information and Inventions Agreement with the Company. 
 I hereby represent that I have been paid all compensation owed and
for all hours worked, have received all the leave and leave benefits and protections for which I am eligible, pursuant to the Family and Medical Leave Act or otherwise, and have not suffered any on-the-job injury for which I have not already filed a
claim. 
 In exchange for the consideration provided to me by this Release that I am not otherwise entitled to receive, I hereby generally and
completely release Jazz Pharmaceuticals plc and its current and former directors, officers, employees, shareholders, partners, agents, attorneys, predecessors, successors, parent and subsidiary entities, insurers, affiliates, and assigns from any
and all claims, liabilities and obligations, both known and unknown, that arise out of or are in any way related to events, acts, conduct, or omissions occurring prior to my signing this Release. This general release includes, but is not limited to:
(a) all claims arising out of or in any way related to my employment with the Company or the termination of that employment; (b) all claims related to my compensation or benefits from the Company, including salary, bonuses, commissions,
vacation pay, expense reimbursements, severance pay, fringe benefits, stock, stock options, or any other ownership interests in the Company; (c) all claims for breach of contract, wrongful termination, and breach of the implied covenant of good
faith and fair dealing; (d) all tort claims, including claims for fraud, defamation, emotional distress, and discharge in violation of public policy; and (e) all federal, state, and local statutory claims, including claims for
discrimination, harassment, retaliation, attorneys’ fees, or other claims arising under the federal Civil Rights Act of 1964 (as amended), the federal Americans with Disabilities Act of 1990, the federal Age Discrimination in Employment Act of
1967 (as amended) (“ADEA”), and the California Fair Employment and Housing Act (as amended). Nothing in this Release shall prevent me from challenging this Release by filing, cooperating with, or participating in any
proceeding before the Equal Employment Opportunity Commission, the Department of Labor, or the California Department of Fair Employment and Housing, except that I hereby acknowledge and agree that I shall not recover any monetary benefits in
connection with any challenge to my Release. 

  
 A-1.

 I acknowledge that I am knowingly and voluntarily waiving and releasing any rights I may have under the ADEA
(“ADEA Waiver”). I also acknowledge that the consideration given for the ADEA Waiver is in addition to anything of value to which I was already entitled. I further acknowledge that I have been advised by this writing, as
required by the ADEA, that: (a) my ADEA Waiver does not apply to any rights or claims that arise after the date I sign this Release; (b) I should consult with an attorney prior to signing this Release; (c) I have twenty-one
(21) days to consider this Release (although I may choose to voluntarily sign it sooner); (d) I have seven (7) days following the date I sign this Release to revoke the ADEA Waiver; and (e) the ADEA Waiver will not be effective
until the date upon which the revocation period has expired unexercised, which will be the eighth day after I sign this Release. 
 I
acknowledge that I have read and understand Section 1542 of the California Civil Code which reads as follows: “A general release does not extend to claims which the creditor does not know or suspect to exist in his or her favor at the
time of executing the release, which if known by him or her must have materially affected his or her settlement with the debtor.” I hereby expressly waive and relinquish all rights and benefits under that section and any law of any
jurisdiction of similar effect with respect to my release of any claims hereunder. 
 I acknowledge that to become effective, I must sign and
return this Release to the Company so that it is received not later than twenty-one (21) days following the date it is provided to me. 
  

			
	EXECUTIVE
		
	Name:	 	  

		
	Date:	 	  

  
 A-2.

 For Employees Age 40 or Older 

Group Termination 

EXHIBIT B 

RELEASE AGREEMENT (“RELEASE”) 
 I understand and agree completely to the terms set forth in the Jazz Pharmaceuticals plc Amended and Restated Executive Change in Control and Severance Benefit Plan (the
“Plan”). 
 I understand that this Release, together with the Plan, constitutes the complete, final and
exclusive embodiment of the entire agreement between the Company and me with regard to the subject matter hereof. I am not relying on any promise or representation by the Company that is not expressly stated therein. Certain capitalized terms used
in this Release are defined in the Plan. 
 I hereby confirm my obligations under my Employee Confidential Information and Inventions
Agreement with the Company. 
 I hereby represent that I have been paid all compensation owed and for all hours worked, have received all
the leave and leave benefits and protections for which I am eligible, pursuant to the Family and Medical Leave Act or otherwise, and have not suffered any on-the-job injury for which I have not already filed a claim. 

Except as otherwise set forth in this Release, I hereby generally and completely release Jazz Pharmaceuticals plc and its current and former directors,
officers, employees, shareholders, partners, agents, attorneys, predecessors, successors, parent and subsidiary entities, insurers, affiliates, and assigns from any and all claims, liabilities and obligations, both known and unknown, that arise out
of or are in any way related to events, acts, conduct, or omissions occurring prior to my signing this Release. This general release includes, but is not limited to: (a) all claims arising out of or in any way related to my employment with the
Company or the termination of that employment; (b) all claims related to my compensation or benefits from the Company, including salary, bonuses, commissions, vacation pay, expense reimbursements, severance pay, fringe benefits, stock, stock
options, or any other ownership interests in the Company; (c) all claims for breach of contract, wrongful termination, and breach of the implied covenant of good faith and fair dealing; (d) all tort claims, including claims for fraud,
defamation, emotional distress, and discharge in violation of public policy; and (e) all federal, state, and local statutory claims, including claims for discrimination, harassment, retaliation, attorneys’ fees, or other claims arising
under the federal Civil Rights Act of 1964 (as amended), the federal Americans with Disabilities Act of 1990, the federal Age Discrimination in Employment Act of 1967 (as amended) (“ADEA”), and the California Fair Employment
and Housing Act (as amended). Nothing in this Release shall prevent me from challenging this Release by filing, cooperating with, or participating in any proceeding before the Equal Employment Opportunity Commission, the Department of Labor, or the
California Department of Fair Employment and Housing, except that I hereby acknowledge and agree that I shall not recover any monetary benefits in connection with any challenge to my Release. 

  
 B-1.

 I acknowledge that I am knowingly and voluntarily waiving and releasing any rights I may have under the ADEA
(“ADEA Waiver”). I also acknowledge that the consideration given for the ADEA Waiver is in addition to anything of value to which I was already entitled. I further acknowledge that I have been advised by this writing, as
required by the ADEA, that: (a) my ADEA Waiver does not apply to any rights or claims that arise after the date I sign this Release; (b) I should consult with an attorney prior to signing this Release; (c) I have forty-five
(45) days to consider this Release (although I may choose to voluntarily sign it sooner); (d) I have seven (7) days following the date I sign this Release to revoke the ADEA Waiver; and (e) the ADEA Waiver will not be effective
until the date upon which the revocation period has expired unexercised, which will be the eighth day after I sign this Release. 
 I have
received with this Release a written disclosure of all of the information required by the ADEA, including without limitation a detailed list of the job titles and ages of all employees who were terminated in this group termination and the ages of
all employees of the Company in the same job classification or organizational unit who were not terminated, along with information on the eligibility factors used to select employees for the group termination and any time limits applicable to this
group termination program. 
 I acknowledge that I have read and understand Section 1542 of the California Civil Code which reads as
follows: “A general release does not extend to claims which the creditor does not know or suspect to exist in his or her favor at the time of executing the release, which if known by him or her must have materially affected his or her
settlement with the debtor.” I hereby expressly waive and relinquish all rights and benefits under that section and any law of any jurisdiction of similar effect with respect to my release of any claims hereunder. 

I acknowledge that to become effective, I must sign and return this Release to the Company so that it is received not later than forty-five
(45) days following the date this Release and the ADEA disclosure form is provided to me. 
  

			
	EXECUTIVE
		
	Name:	 	  

		
	Date:	 	  

  
 B-2.

 For Employees under Age 40 

Individual and Group Termination 
 EXHIBIT C 
 RELEASE AGREEMENT (“RELEASE”)

 I understand and agree completely to the terms set forth in the Jazz Pharmaceuticals plc Amended and Restated Executive Change in
Control and Severance Benefit Plan (the “Plan”). 
 I understand that this Release, together with the Plan,
constitutes the complete, final and exclusive embodiment of the entire agreement between the Company and me with regard to the subject matter hereof. I am not relying on any promise or representation by the Company that is not expressly stated
therein. Certain capitalized terms used in this Release are defined in the Plan. 
 I hereby confirm my obligations under my Employee
Confidential Information and Inventions Agreement with the Company. 
 I hereby represent that I have been paid all compensation owed and
for all hours worked, have received all the leave and leave benefits and protections for which I am eligible, pursuant to the Family and Medical Leave Act or otherwise, and have not suffered any on-the-job injury for which I have not already filed a
claim. 
 In exchange for the consideration provided to me by this Release that I am not otherwise entitled to receive, I hereby generally and
completely release Jazz Pharmaceuticals plc and its current and former directors, officers, employees, shareholders, partners, agents, attorneys, predecessors, successors, parent and subsidiary entities, insurers, affiliates, and assigns from any
and all claims, liabilities and obligations, both known and unknown, that arise out of or are in any way related to events, acts, conduct, or omissions occurring prior to my signing this Release. This general release includes, but is not limited to:
(a) all claims arising out of or in any way related to my employment with the Company or the termination of that employment; (b) all claims related to my compensation or benefits from the Company, including salary, bonuses, commissions,
vacation pay, expense reimbursements, severance pay, fringe benefits, stock, stock options, or any other ownership interests in the Company; (c) all claims for breach of contract, wrongful termination, and breach of the implied covenant of good
faith and fair dealing; (d) all tort claims, including claims for fraud, defamation, emotional distress, and discharge in violation of public policy; and (e) all federal, state, and local statutory claims, including claims for
discrimination, harassment, retaliation, attorneys’ fees, or other claims arising under the federal Civil Rights Act of 1964 (as amended), the federal Americans with Disabilities Act of 1990, and the California Fair Employment and Housing Act
(as amended). Nothing in this Release shall prevent me from challenging this Release by filing, cooperating with, or participating in any proceeding before the Equal Employment Opportunity Commission, the Department of Labor, or the California
Department of Fair Employment and Housing, except that I hereby acknowledge and agree that I shall not recover any monetary benefits in connection with any challenge to my Release. 

  
 C-1.

 I acknowledge that I have read and understand Section 1542 of the California Civil Code which reads as
follows: “A general release does not extend to claims which the creditor does not know or suspect to exist in his or her favor at the time of executing the release, which if known by him or her must have materially affected his or her
settlement with the debtor.” I hereby expressly waive and relinquish all rights and benefits under that section and any law of any jurisdiction of similar effect with respect to my release of any claims hereunder. 

I acknowledge that to become effective, I must sign and return this Release to the Company so that it is received not later than fourteen (14) days
following the date it is provided to me. 
  

			
	EXECUTIVE
		
	Name:	 	  

		
	Date:	 	  

  
 C-2.<![CDATA[First Amendment to amend and retated Revolving Credit & Security Agreement]]>

 [Confidential Treatment Requested. Confidential portions of this document have been
redacted and have been separately filed with the Securities and Exchange Commission] 
 FIRST AMENDMENT TO AMENDED AND
RESTATED REVOLVING 
 CREDIT AND SECURITY AGREEMENT 

THIS FIRST AMENDMENT TO AMENDED AND RESTATED REVOLVING CREDIT AND SECURITY AGREEMENT (this “Amendment”) is entered into
on this 26th day of March, 2012 (the “Effective Date”), by and among NEOGENOMICS LABORATORIES, INC., a Florida corporation (“Borrower”), NEOGENOMICS, INC., a Nevada corporation
(“Guarantor”, together with Borrower, individually, a “Credit Party” and collectively, the “Credit Parties”) and CAPITALSOURCE FINANCE LLC, a Delaware limited liability company
(“Lender”) as agent for the lenders to the Credit Agreement. 
 RECITALS 

A. The Credit Parties and Lender have entered into that certain Amended and Restated Revolving Credit and Security Agreement, dated as of
April 26, 2010 (as may be amended, restated, supplemented or otherwise modified from time to time, the “Credit Agreement”). 
 B. The Credit Parties have requested that Lender agree to make certain amendments to the Credit Agreement. Lender has agreed to this request on the conditions set forth in this Agreement. 

C. Pursuant to the terms and conditions of this Amendment, the Credit Parties and the Lender have agreed to amend certain provisions of
the Credit Agreement. 
 NOW, THEREFORE, in consideration of the premises herein contained and other good and valuable
consideration, the receipt and sufficiency of which are hereby acknowledged, the parties, intending to be legally bound, agree as follows: 
 AGREEMENT 
 ARTICLE I - DEFINITIONS 

1.01 Definitions. Capitalized terms used in this Amendment are defined in the Credit Agreement, as amended hereby, unless
otherwise stated. 
 ARTICLE II – AMENDMENT 

2.01 Amendment to Recitals of the Credit Agreement. 

(a) The First recital of the Credit Agreement is hereby amended by deleting it in its entirety. 

 (b) The Second recital of the Credit Agreement is hereby amended by deleting such section in
its entirety and replacing it with the following: 
 WHEREAS, Borrower has requested that Lender make
available to Borrower a revolving credit facility (the “Revolving Facility”) in a maximum principal amount at any time outstanding of up to Eight Million and 00/100 Dollars ($8,000,000.00) (such amount as of the date hereof
and as such amount may be increased from time to time as provided in Section 2.1(d) of this Agreement, the “Facility Cap”), the proceeds of which shall be used by Borrower as a provider of healthcare services and
for the generation and/or acquisition of Accounts, and for other lawful purposes not prohibited hereunder; 
 2.02
Amendment to Section 1.2 of the Credit Agreement. Effective as of the Effective Date, Section 1.2 is hereby amended as follows: 
 (a) The definition of “Facility Cap” is hereby deleted in its entirety and replaced with the following: 
 “Facility Cap” shall have the meaning assigned to such term in the first Recital and shall include any increase in the principal amount thereof pursuant to Section 2.1.

 (b) The definition of “Minimum Termination Fee” is hereby deleted in its entirety and replaced with the following:

 “Minimum Termination Fee” shall mean (for the time period indicated) the amount equal to
(i) 2.5% of the Facility Cap, if the Revolver Termination is at any time before March 26, 2013; (ii) 1.5% of the Facility Cap, if the Revolver Termination is after March 26, 2013 but before March 26, 2014; and
(iii) 0.5% of the Facility Cap, if the Revolver Termination is on or after March 26, 2014. There shall be no Minimum Termination Fee if the Revolver Termination occurs within five (5) days of the end of the Term. 

(c) The definition of “Permitted Indebtedness” is modified as follows: 

Subparagraph (iii) is hereby deleted in its entirety and replaced with the following: 

(iii) Capitalized Lease Obligations and Indebtedness incurred to purchase Goods and secured by purchase money Liens
constituting Permitted Liens: (A) in aggregate amount outstanding at any time not to exceed (1) $12,000,000 at any time before March 26, 2013, (2) $15,000,000 on or after March 26, 2013 but before March 26, 2014, and
(3) $18,000,000 on or after March 26, 2014, in each of (1), (2) and (3) less the outstanding amount of such Indebtedness identified on Schedule 9.2 upon the incurrence of such Indebtedness and after giving effect thereto
no Default or Event of Default shall exist and be continuing and (B) in an aggregate amount in excess of any of the thresholds specified in subparagraph (A), provided, that, (1) ten (10) Business Days prior to the
incurrence of such Indebtedness Borrower shall have provided pro forma financial statements along with any other supporting documentation required by Lender evidencing that Borrower would have been in compliance with the financial covenants set
forth on Annex 1 hereto for the immediately preceding Test Period (as defined on Annex 1 hereto), if such Indebtedness had been incurred on the first day of such Test Period, (2) prior to the incurrence of such Indebtedness Borrower shall have
received Lender’s written confirmation of its agreement with such pro forma financial statements; and (3) upon the incurrence of such Indebtedness and after giving effect thereto no Default or Event of Default shall exist and be
continuing, 

  
 2 

 (d) The definition of “Term” is hereby deleted in its entirety and replaced with
the following: 
 “Term” shall mean the period commencing on the Closing Date and ending on
March 26, 2015. 
 2.03 Amendment to Section 2.1 of the Credit Agreement. Effective as of the Effective
Date Section 2.1 of the Credit Agreement is hereby amended by adding the following new clause (d) at the end of such section: 
 (d) Borrower may, no more than twice during the Term of this Agreement, request to increase the amount of the Facility Cap as in effect on any date of determination; provided, that, in
connection with any such request, Borrower shall (x) provide such request in writing, (y) certify to Lender that no Default or Event of Default has occurred and is continuing or would be caused by such request, and (z) state the
requested effective date of such increase in the Facility Cap, which in no event may be more than forty-five (45) or less than fifteen (15) Business Days after the date of such request. All such requests shall be made in increments of
$1,000,000. Upon Lender’s written consent to such request, which consent may be granted or withheld by Lender in Lender’s sole discretion, and upon payment by Borrower to Lender of a commitment fee equal to 1% of the requested increase in
the Facility Cap, Borrower’s requested increase of the Facility Cap will become effective on the date requested. 
 2.04
Amendment to Section 3.1 of the Credit Agreement. Effective as of the Effective Date, Section 3.1 of the Credit Agreement is hereby amended and restated by deleting “the LIBOR shall be not less than 2.0%” from
such section and replacing it with “the LIBOR shall be not less than 1.0%”. 

  
 3 

 2.05 Amendment to Section 8.7 of the Credit Agreement. Effective as of
the Effective Date, clause (A) of Section 8.7 of the Credit Agreement is hereby deleted in its entirety and replaced with the following: 
 (A) Borrower shall not be obligated to reimburse Lender for more than two (2) visits, inspections, examinations and audits under the foregoing clause (i) conducted during any fiscal year while
no Default or Event of Default exists and the maximum expenses charged to Borrower under each such audit shall be the lesser of (1) $12,500 or (2) the sum of $850 per auditor per day plus all out-of-pocket expenses of Lender (it being
agreed and understood that the Borrower shall be Obligated to reimburse Lender for all such visits, inspections, examinations and audits conducted while any Default or Event of Default exists). Lender agrees to provide Borrower an invoice detailing
the costs including the number of man hours expended and the expenses of each such audit at least ten (10) Business Days prior to charging such amounts as an Advance under the Revolving Facility; and 

2.06 Amendment to Section 13.1(a) of the Credit Agreement. Effective as of the Effective Date,
Section 13.1(a) of the Credit Agreement is hereby amended by: 
 (a) deleting “thirty calendar” from the
second sentence of such section and replacing it with “fifteen calendar”; and 
 (b) deleting “thirty (30)”
from the third sentence of such section and replacing it with “fifteen (15)”. 
 2.07 Amendment to Annex I of
the Credit Agreement. Effective as of the Effective Date, Annex I of the Credit Agreement is hereby amended by deleting the definition of “Fixed Charge Coverage Ratio” in its entirety and replacing it with the following:

 “Fixed Charge Coverage Ratio” shall mean, as of any date of determination, for Borrower
collectively on a consolidated basis, the ratio of (a) the sum of Adjusted EBITDA for the Test Period ended as of such date plus an amount equal to the daily average for the immediately preceding month of the sum of unrestricted cash on hand,
unrestricted Cash Equivalents and unused Availability for the last month of the Test Period ended as of such date, to (b) Fixed Charges for the Test Period ended as of such date. 

2.08 Amendment to Schedules to Credit Agreement. Effective as of the Effective Date the Schedules to the Credit Agreement
are deleted in their entirety and replaced with the Schedules attached as Exhibit A hereto. 
 ARTICLE III-
CONDITIONS PRECEDENT 
 3.01 Conditions to Effectiveness. The effectiveness of this Amendment against
Lender is subject to the satisfaction of the following conditions precedent in a manner satisfactory to Lender in its sole discretion, unless specifically waived in writing by Lender: 

(a) Lender shall have received this Amendment duly executed by each party thereto; 

  
 4 

 (b) the representations and warranties contained herein and in all other Loan Documents
shall be true and correct in all material respects (without duplication of any materiality qualifiers contained in the Loan Documents); 
 (c) no Default or Event of Default shall be in existence; 
 (d) Lender shall have
received all fees, charges and expenses payable to Lender as required by this Amendment, including the Commitment Fee (as hereinafter defined), and in connection with this Amendment and the documentation related hereto, including, but not limited
to, reasonable legal fees and out-of-pocket costs, (including reasonable in-house counsel fees and expenses), and Borrower hereby authorize Lender to charge such amounts as an Advance under the Revolving Facility; 

(e) Lender shall have received Good Standing Documents of Borrower; 

(f) Lender shall have received a certificate of the corporate secretary or assistant secretary of each Borrower dated as of the date
hereof, certifying the resolutions of the Board of Directors of each Credit Party authorizing the execution of this Amendment, in form and substance acceptable to Lender; and 
 (g) Lender shall have received an updated report of Uniform Commercial Code financing statement, tax and judgment lien searches performed with respect to Borrower in each jurisdiction determined by Lender
in its sole discretion, and such report shall show no Liens on the Collateral (other than Permitted Liens), required by any Loan Document or under law or requested by Lender to be filed, registered or recorded to create in favor of Lender, a
perfected first priority security interest upon the Collateral; 
 ARTICLE IV- RATIFICATIONS, REPRESENTATIONS AND
WARRANTIES 
 4.01 Ratifications. The terms and provisions set forth in this Amendment shall modify and
supersede all inconsistent terms and provisions set forth in the Credit Agreement and the Loan Documents, and, except as expressly modified and superseded by this Amendment, the terms and provisions of the Credit Agreement and the Loan Documents are
ratified and confirmed and shall continue in full force and effect. The Credit Parties hereby ratify and confirm that the Liens granted under the Credit Agreement secure all obligations and indebtedness now, hereafter or from time to time made by,
owing to or arising in favor of Lender pursuant to the Loan Documents (as now, hereafter or from time to time amended). The Credit Parties and Lender agree that the Credit Agreement and the Loan Documents, as amended hereby, shall continue to be
legal, valid, binding and enforceable in accordance with their respective terms. 
 4.02 Representations and
Warranties. The Credit Parties hereby, jointly and severally, represent and warrant to Lender that: 
 (a) The
representations and warranties made by the Credit Parties (other than those made as of a specific date) contained in the Credit Agreement, as amended hereby, and each Loan Document are true and correct in all material respects (except that, for
those representations and warranties already qualified by concepts of materiality, those representations and warranties shall be true and correct in all respects) on and as of the date hereof and as of the date of execution hereof as though made on
and as of each such date; 

  
 5 

 (b) No Default or Event of Default under the Credit Agreement, as amended hereby, has
occurred and is continuing; 
 (c) No Borrower has amended its certificate of incorporation or bylaws (or any other equivalent
governing agreement or document), as applicable, since the date of the Credit Agreement; 
 ARTICLE V – COMMITMENT FEE

 5.01 Commitment Fee. Borrower agrees to pay Lender $80,000 as a commitment fee (the “Commitment
Fee”), which fee shall be due and payable on the date hereof. Borrower hereby authorizes Lender to charge such fee as an Advance on the date hereof and shall be fully earned by Lender when so charged. 

ARTICLE VI – MISCELLANEOUS PROVISIONS 
 6.01 Survival of Representations and Warranties. All representations and warranties made in the Credit Agreement, or any Loan Document, including, without limitation, any document furnished
in connection with this Amendment, shall survive the execution and delivery of this Amendment and the Loan Documents, and no investigation by Lender or any closing shall affect the representations and warranties or the right of Lender to rely upon
them. 
 6.02 Reference to Credit Agreement. Each of the Credit Agreement and the Loan Documents, and any and all
Loan Documents, documents or instruments now or hereafter executed and delivered pursuant to the terms hereof or pursuant to the terms of the Credit Agreement, as amended hereby, are hereby amended so that any reference in the Credit Agreement and
such Loan Documents to the Credit Agreement shall mean a reference to the Credit Agreement, as amended hereby. 
 6.03
Expenses of Lender. As provided in the Credit Agreement, the Credit Parties agree to pay on demand all costs and expenses incurred by Lender in connection with the preparation, negotiation, and execution of this Amendment and the Loan
Documents executed pursuant hereto and any and all amendments, modifications, and supplements thereto, including, without limitation, the reasonable costs and fees of Lender’s legal counsel, and all costs and expenses incurred by Lender in
connection with the enforcement or preservation of any rights under the Credit Agreement, as amended hereby, or any Loan Documents, including, without, limitation, the reasonable costs and fees of Lender’s legal counsel. Notwithstanding the
forgoing, Lender agrees that its fees and expenses in connection with the preparation, negotiation, and execution of this Amendment shall not exceed $10,000 unless otherwise agreed upon in writing by the Borrower. 

6.04 Severability. Any provision of this Amendment held by a court of competent jurisdiction to be invalid or unenforceable
shall not impair or invalidate the remainder of this Amendment and the effect thereof shall be confined to the provision so held to be invalid or unenforceable. 

  
 6 

 6.05 Successors and Assigns. This Amendment is binding upon and shall inure to
the benefit of Lender and the Credit Parties and their respective successors and assigns, except that the Credit Parties may not assign or transfer any of their rights or obligations hereunder without the prior written consent of Lender. 

6.06 Counterparts. This Amendment may be executed in one or more counterparts, each of which when so executed shall be
deemed to be an original, but all of which when taken together shall constitute one and the same instrument. Any signature delivered by a party by facsimile or other electronic transmission shall be deemed to be an original signature hereto.

 6.07 Effect of Waiver. No consent or waiver, express or implied, by Lender to or for any breach of or deviation
from any covenant or condition by the Credit Parties shall be deemed a consent to or waiver of any other breach of the same or any other covenant, condition or duty. 
 6.08 Headings. The headings, captions, and arrangements used in this Amendment are for convenience only and shall not affect the interpretation of this Amendment. 

6.09 Applicable Law. THIS AMENDMENT AND ALL LOAN DOCUMENTS EXECUTED PURSUANT HERETO SHALL BE DEEMED TO HAVE BEEN MADE AND
TO BE PERFORMABLE IN AND SHALL BE GOVERNED BY AND CONSTRUED IN ACCORDANCE WITH THE CHOICE OF LAW SET FORTH IN THE CREDIT AGREEMENT. 
 6.10 Final Agreement. THE CREDIT AGREEMENT AND THE LOAN DOCUMENTS, EACH AS AMENDED HEREBY, REPRESENT THE ENTIRE EXPRESSION OF THE PARTIES WITH RESPECT TO THE SUBJECT MATTER HEREOF ON THE
DATE THIS AMENDMENT IS EXECUTED. THE CREDIT AGREEMENT AND THE LOAN DOCUMENTS, AS AMENDED HEREBY, MAY NOT BE CONTRADICTED BY EVIDENCE OF PRIOR, CONTEMPORANEOUS OR SUBSEQUENT ORAL AGREEMENTS OF THE PARTIES. THERE ARE NO UNWRITTEN ORAL AGREEMENTS
BETWEEN THE PARTIES. NO MODIFICATION, RESCISSION, WAIVER, RELEASE OR AGREEMENT OF ANY PROVISION OF THIS AMENDMENT SHALL BE MADE, EXCEPT BY A WRITTEN AGREEMENT SIGNED BY THE CREDIT PARTIES AND LENDER. 

  
 7 

 6.11 Release. THE CREDIT PARTIES HEREBY ACKNOWLEDGE THAT THEY HAVE NO DEFENSE,
COUNTERCLAIM, OFFSET, CROSS-COMPLAINT, CLAIM OR DEMAND OF ANY KIND OR NATURE WHATSOEVER THAT CAN BE ASSERTED TO REDUCE OR ELIMINATE ALL OR ANY PART OF ITS LIABILITY TO REPAY THE “OBLIGATIONS” OR TO SEEK AFFIRMATIVE RELIEF OR DAMAGES OF ANY
KIND OR NATURE FROM LENDER. THE CREDIT PARTIES HEREBY VOLUNTARILY AND KNOWINGLY RELEASE AND FOREVER DISCHARGE LENDER AND LENDERS, AND ANY OF THEIR RESPECTIVE PREDECESSORS, AGENTS, ATTORNEYS, EMPLOYEES, AFFILIATES, SUCCESSORS AND ASSIGNS, FROM ALL
POSSIBLE CLAIMS, DEMANDS, ACTIONS, CAUSES OF ACTION, DAMAGES, COSTS, EXPENSES, AND LIABILITIES WHATSOEVER, KNOWN OR UNKNOWN, ANTICIPATED OR UNANTICIPATED, SUSPECTED OR UNSUSPECTED, FIXED, CONTINGENT, OR CONDITIONAL, AT LAW OR IN EQUITY, ORIGINATING
IN WHOLE OR IN PART ON OR BEFORE THE DATE THIS AMENDMENT IS EXECUTED, WHICH THE CREDIT PARTIES MAY NOW OR HEREAFTER HAVE AGAINST LENDER, OR ANY OF THEIR RESPECTIVE PREDECESSORS, ATTORNEYS, AGENTS, EMPLOYEES, AFFILIATES, SUCCESSORS AND ASSIGNS, IF
ANY, AND IRRESPECTIVE OF WHETHER ANY SUCH CLAIMS ARISE OUT OF CONTRACT, TORT, VIOLATION OF LAW OR REGULATIONS, OR OTHERWISE, AND ARISING FROM ANY “LOANS”, INCLUDING, WITHOUT LIMITATION, ANY CONTRACTING FOR, CHARGING, TAKING, RESERVING,
COLLECTING OR RECEIVING INTEREST IN EXCESS OF THE HIGHEST LAWFUL RATE APPLICABLE, THE EXERCISE OF ANY RIGHTS AND REMEDIES UNDER THE CREDIT AGREEMENT OR LOAN DOCUMENTS, AND NEGOTIATION FOR AND EXECUTION OF THIS AMENDMENT. 

[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK] 

  
 8 

 IN WITNESS WHEREOF, this Amendment has been executed and is effective as of the date first
written above. 
  

			
	BORROWER:
	
	NEOGENOMICS LABORATORIES, INC., a Florida corporation
		
	By:	 	 /s/ Douglas VanOort

	Name:	 	Douglas VanOort
	Title:	 	Chairman and CEO
	
	GUARANTOR:
	
	NEOGENOMICS, INC., a Nevada corporation
		
	By:	 	 /s/ Douglas VanOort

	Name:	 	Douglas VanOort
	Title:	 	Chairman and CEO
	
	LENDER:
	
	 CAPITALSOURCE FINANCE LLC, as agent
 for the lenders

		
	By:	 	 /s/ J. Stephen Klose

	Name:	 	J. Stephen Klose
	Title:	 	Authorized Signatory

  
 9 

 EXHIBIT A 

AMENDED AND RESTATED CREDIT AGREEMENT SCHEDULES 

 

			
	Schedule 1.2	  	 Accounts Payable Over 120 Days That Are Permitted Indebtedness:

 
 Aspen Capital Advisors not to exceed $65,000

K&L Gates, LLP not to exceed $500,000
 HCSS, LLC dba Bridge Labs not to exceed $40,000

		
	Schedule 2.3	  	Borrower’s Operating Account for Disbursements

  

			
	 Bank Name:
	  	[***]
	 ABA #:
	  	[***]
	 City/State:
	  	[***]
	 Account #:
	  	[***]
	 Account Name:
	  	[***]

  

			
		
	Schedule 5.3B	  	 Third-Party Contracts With Payor’s Representing at Least 5% of Cash Receipts

 
 Medicare

United Healthcare
 Blue Cross/Blue Shield of Florida 7/1/2009

		
	Schedule 7.3	  	 Subsidiaries of NeoGenomics, Inc., a Nevada Corporation (Holding Company)

 
 NeoGenomics Laboratories, Inc., a Florida Corporation

NeoGenomics California Laboratories, LLC, a California limited liability company (currently inactive)

 
 Subsidiaries of NeoGenomics Laboratories, Inc., a Florida Corporation (Operating
Company)
  
 None

		
		  	Capitalization of NeoGenomics, Inc, a Nevada Corporation

  

					
	 Common Shares Authorized:
	  	 	100,000,000	  
	 Common Stock Outstanding (as of 03/08/2012):
	  	 	44,835,817	  
		
	 Preferred Stock Authorized:
	  	 	10,000,000	  
	 Preferred Stock Outstanding (as of 03/08/2012):
	  	 	None	  
		
	 Warrants Outstanding (as of 03/08/2012):
	  	 	2,256,750	  
	 Options Outstanding (as of 03/08/2012):
	  	 	5,857,083	  

  

			
		  	This Schedule 7.3 dealing with the Capitalization of the Guarantor shall be deemed to be automatically updated by any disclosures which appear in the Guarantor’s public filings
with the Securities and Exchange Commission.
		
		  	Capitalization of NeoGenomics Laboratories, Inc, a Florida Corporation

  

					
	 Common Shares Authorized:
	  	 	100	  
	 Common Sock Outstanding:
	  	 	100	  

 [***] Information redacted pursuant to a confidential treatment request. An unredacted version of this Agreement has been
filed separately with the Securities and Exchange Commission. 

  
 1 

					
		  	Board of Directors of NeoGenomics, Inc., a Nevada Corporation
			
		  	 Michael T. Dent, M.D.
	  	Kevin C. Johnson
		  	 Robert P. Gasparini
	  	Peter M. Peterson
		  	 Raymond R. Hipp
	  	William J. Robison
		  	 Steven C. Jones
	  	Douglas M. VanOort
		
		  	Board of Directors of NeoGenomics Laboratories, Inc., a Florida Corporation
			
		  	 Douglas M. VanOort
 Steven C. Jones
 Robert P. Gasparini
	  	
			
	Schedule 7.4A	  	 Locations of Leased Properties
  

12701 Commonwealth Drive, Suites 1-9
 Fort Myers, FL 33913
  
 618 Grassmere Park Drive, Suite 20
 Nashville, TN 37211

 
 6 Morgan Street, Suite’s 116,130 and 150

Irvine, CA 92618
  

10002 Princess Palm Avenue, Suite 228
 Tampa, FL 33619
	  	
		
	Schedule 7.4B	  	Deposit Accounts of NeoGenomics, Inc., a Nevada Company (Holding Company)

  

									
	 Bank
	  	Account #	 	  	Description	 
	 [***]
	  	 	[***]	  	  	 	[***]	  
	 [***]
	  	 	[***]	  	  	 	[***]	  
	 [***]
	  	 	[***]	  	  	 	[***]	  
	 [***]
	  	 	[***]	  	  	 	[***]	  
	 [***]
	  	 	[***]	  	  	 	[***]	  
	 [***]
	  	 	[***]	  	  	 	[***]	  

  

			
		 	Deposit Accounts of NeoGenomics Laboratories, Inc., a FL Company (Operating Subsidiary)

  

									
	 Bank
	  	Account #	 	  	Description	 
	 [***]
	  	 	[***]	  	  	 	[***]	  
	 [***]
	  	 	[***]	  	  	 	[***]	  
	 [***]
	  	 	[***]	  	  	 	[***]	  
	 [***]
	  	 	[***]	  	  	 	[***]	  
	 [***]
	  	 	[***]	  	  	 	[***]	  
	 [***]
	  	 	[***]	  	  	 	[***]	  
	 [***]
	  	 	[***]	  	  	 	[***]	  
	 [***]
	  	 	[***]	  	  	 	[***]	  
	 [***]
	  	 	[***]	  	  	 	[***]	  

 [***] Information redacted pursuant to a confidential treatment request. An unredacted version of this Agreement has been
filed separately with the Securities and Exchange Commission. 

  
 2 

			
	Schedule 7.5	  	 Affiliate Contracts
  

Consulting Agreement
  

During 2011 and 2010, Steven Jones, a director of the Company, earned $198,334 and $201,850, respectively, for various consulting work
performed in connection with his duties as Executive Vice President of Finance. Mr. Jones is a member of the Board of Directors Compliance Committee and was a member of the Compensation Committee through May of 2010.

 
 On May 3, 2010, the Company entered into a consulting
agreement (the “Consulting Agreement”) with Steven Jones (the “Consultant” or “Mr. Jones”) whereby Mr. Jones would continue to provide consulting services to the Company in the capacity of Executive Vice President of
Finance. The Consulting Agreement has an initial term from May 3, 2010 through April 30, 2013, which initial term automatically renews for additional one year periods unless either party provides notice of termination at least three months
prior to the expiration of the initial term or any renewal term. In addition, the Company has the right to terminate the Consulting Agreement by giving written notice to the Consultant twelve months prior to the effective date of termination. The
Consultant has the right to terminate the Consulting Agreement by giving written notice to the Company three months prior to the proposed termination date, provided, however, the Consultant is required to provide an additional three months of
transition services to the Company upon reasonable request by the Company. The Consulting Agreement specifies an annual base retainer compensation of $180,000 per year, which was subsequently increased to $200,000 per year in February 2011. Mr.
Jones is also eligible to receive an annual cash bonus based on the achievement of certain performance metrics with a target of 30% of his base retainer. Such bonus is eligible to be increased to up to 150% of the target bonus in any fiscal year in
which he meets certain performance thresholds established by the CEO of the Company and approved by the Board of Directors.
  

The Company also agreed that it would issue to the Consultant a warrant to purchase 450,000 shares of the Company’s common stock.
The warrant has a) a seven year term, b) an exercise price of $1.50 per share, c) the ability to do a cashless net exercise, and d) vesting as follows:
  

i) 225,000 of such warrant shares vested immediately which included recognition for cumulative achievements for the Company by Mr.
Jones; and
  
 ii) 112,500 of such warrant shares vest
according to the passage of time, with 4,687 warrant shares vesting on the last day of each calendar month for twenty-three (23) months, beginning with the month ended May 31, 2010 and continuing until the month ending March 31, 2012 and
4,699 warrant shares vest on April 30, 2012 so long as Consultant continues to provide services to the Company pursuant to this Agreement or any successor agreement.

 
 iii) 112,500 of such warrant shares vested based on the Company
meeting certain financial goals.
  
 The Consulting
Agreement also provides that the vesting schedule of such warrant shall also specify that any unvested warrant shares shall vest upon the occurrence of a change of control.

 
 This Schedule 7.5 as it relates to Affiliate Contracts with Mr.
Steven Jones shall be deemed to be automatically updated by any disclosures which appear in the Guarantor’s public filings with the Securities and Exchange Commission.

  
 3 

			
		  	 Laboratory Information System
  

On March 11, 2005, we entered into an agreement with HCSS, LLC and eTelenext, Inc. to enable NeoGenomics to use eTelenext’s
Accessioning Application, AP Anywhere Application and CMQ Application. HCSS, LLC was owned 66.7% by Dr. Michael T. Dent, a member of our Board of Directors. On June 18, 2009, we entered into a Software Development, License and Support Agreement with
HCSS, LLC and eTelenext, Inc. to upgrade the Company’s laboratory information system to a new version called APvX. This agreement had an initial term of 5 years from the date of acceptance and called for monthly fees of $8,000-$12,000 during
the term. In June 2010, HCSS and eTelenext were merged into eTelenext’s parent company, PathCentral, Inc. Dr. Dent owned approximately 3% of PathCentral, Inc. at December 31, 2010. In May 2011, PathCentral, Inc. agreed to provide the source
code of our APVX installation to us in exchange for a release of any further obligations to NeoGenomics and in connection with such transaction our agreement with PathCentral, Inc. was terminated. During the years ended December 31, 2011 and 2010,
we incurred licensing and software customization fees from HCSS/eTelenext/PathCentral, Inc. of approximately $97,506 and approximately $286,000, respectively.
  

Gulf Pointe Capital Lease Agreement
  

On September 30, 2008, we entered into a master lease agreement (the “Master Lease”) with Gulf Pointe Capital, LLC
(“Gulf Pointe”) which provided for $130,000 of lease financing after it was determined that the lease facility with Leasing Technologies, Inc. would not allow for the leasing of certain used and other types of equipment. Three members of
our Board of Directors at the time we entered into the Master Lease, Steven Jones, Peter Petersen and Marvin Jaffe, were affiliated with Gulf Pointe and recused themselves from both sides of all negotiations concerning this transaction. The terms
under this lease are consistent with the terms of our other lease arrangements and provided for the sale/leaseback of approximately $130,000 of used laboratory equipment. The lease had a 30 month term and called for monthly payments of $5,155. In
consideration for entering into the Master Lease, the Company issued 32,475 common stock warrants to Gulf Pointe with an exercise price of $1.08 and a five year term. The warrants were valued at approximately $11,000 using the Black-Scholes option
pricing model. This first lease schedule under the master lease agreement was completed in July 2011, and the Company elected to exercise its end of lease option to purchase the equipment for $16,887.

 
 On February 9, 2009, we amended our Master Lease with Gulf
Pointe to increase the maximum size of the facility to $250,000 and entered into a second schedule under the Master Lease for the sale/leaseback of approximately $118,000 of used laboratory equipment. This second lease had a 30 month term at the
same lease rate factor per month as the first lease, which equates to monthly payments of $4,690. As part of this amendment, we terminated the original warrant agreement dated September 30, 2009 and replaced it with a new warrant to purchase 83,333
shares of our common stock. Such new warrants have a five year term, an exercise price of $0.75 per share and the same vesting schedule as the original warrants. The replacement warrants were valued using the Black-Scholes option pricing model and
the value did not materially differ from the valuation of the original warrants they replaced. This second lease schedule was completed in December 2011, and the Company elected to exercise its end of lease option to purchase the equipment for
$13,039.

  
 4 

			
		  	 Research DX, LLC
  

During 2009, we began contracting with ResearchDX, L.L.C. (“ResearchDX”) to provide clinical trial management services on
our behalf. During 2010, we began to receive various specimens for testing from ResearchDX and we continued to outsource our clinical trial management and cytogenetic overflow testing volume to them for processing. Matthew Moore, our former Vice
President of Research and Development until March 31, 2011 owned 50% of ResearchDX. During the years ended December 31, 2011 and 2010, we received specimen testing revenue of approximately $63,000 and $33,000, respectively and incurred expenses of
approximately $339,000 and $233,000, respectively with ResearchDX.
  

Sale of Securities
  

Between January 10, 2011 and January 12, 2011, the Parent Company entered into subscription agreements (the “Subscription
Agreements”) with certain investors (the “Investors”) pursuant to which the Parent Company has sold to the Investors an aggregate of 2,001,667 shares of the Parent Company’s common stock, at a price of $1.50 per share
(the “Common Stock Financing”). In connection with the Common Stock Financing, the Parent Company also entered into registration rights agreements with the Investors.

 
 The Investors included, among others, (i) the Douglas M. VanOort
Living Trust (of which Douglas VanOort, Chief Executive Officer and Chairman of the Company’s Board of Directors, is affiliated), (ii) the Steven and Carisa Jones Defined Benefit Pension Plan & Trust (of which Steven Jones, Executive
Vice President – Finance and a director of the Company, is affiliated), (iii) The George A. Cardoza Family Trust (of which George Cardoza, the Company’s Chief Financial Officer, is affiliated), (iv) Mark W. Smits (who was previously the
Company’s Vice President of Sales and Marketing) and (v) Kevin C. Johnson (who is a director of the Company).
  
 Strategic Supply Agreement
  
 On July 24,2009, NeoGenomics Laboratories, Inc. and Abbott Molecular Inc., a Delaware corporation (“Abbott Molecular”), entered into a Strategic Supply Agreement (the “Supply
Agreement”). The Supply Agreement, among other things, provides for Abbott Molecular to supply materials with which NeoGenomics Laboratories intends to develop its own FISH (fluorescence in situ hybridization)-based test for the diagnosis of
malignant melanoma in skin biopsy specimens (excluding subtyping) (the “Melanoma LDT”).

		
	Schedule 7.6	  	 Litigation
  

CURRENTLY PENDING LITIGATION:
  

EEOC Complaints Filed by Two Former Sales Representatives

 
 In December 2010, the Company was notified that two
former sales representatives, Sharon Lang and Michael Howachyn, had filed Age Discrimination Complaints against the Company with the Equal Employment Opportunity Commission (EEOC) one day prior to their being terminated [***]. [***]. The Company did
a thorough investigation of the alleged allegations upon learning about them, and believes there is no basis to any of the claims made. Pursuant to EEOC policy, the Company tried to settle each case, but was not successful. The EEOC has issued a
“Right to Sue” letter to Ms. Lang, but has not yet done so for Mr. Howachyn.
  

	 	[***]	Information redacted pursuant to a confidential treatment request. An unredacted version of this Agreement has been filed separately with the Securities and Exchange
Commission. 

  

  
 5 

			
		  	  
 On October 12, 2011, Counsel for Ms. Lang
filed a complaint in the United States District Court for the Northern District of Illinois alleging that the Company engaged in Age Discrimination against her. The Company responded to the allegations on December 12, 2011. On December 14, 2011, Ms.
Lang’s attorney offered to settle the case in exchange for $60,000. The Company countered with a $5,000 settlement offer. On December 30, 2011, the Company received Ms. Lang’s Rule 26 disclosures. There was no new material in these
disclosures. On January 25, 2012, Judge Kennelly conducted a court-initiated, teleconference to review the status of the case and inquire about a possible settlement. The Judge set another telephonic status conference for February 23, 2012 at
8:45 a.m. for the parties to report on their settlement progress and case status. As NeoGenomics has decided not to offer anything further toward a settlement at this time, the Company expects the Judge to refer the matter to a Magistrate to
conduct a settlement conference. No hearings or meeting of any kind have been scheduled as of yet on the Lang matter, but the Company plans to file a motion to change the venue to the Federal Courts sitting in Florida in the next
week.
  
 [***].[***].[***]. Thus, even in the event that
the Company was found liable for Ms. Lang’s claims, the Company does not believe the amounts in question would be material to the ongoing operations of the Company.

 
 [***].[***]. If the Company were found liable for Mr.
Howachyn’s claims, the Company does not believe the amounts in question would be material to the ongoing operations of the Company.
  

Katherine Elias
  

On April 8, 2010, the Company was served with a complaint by Ms. Katherine Elias, a former sales representative of the Company who was
employed from October 2007 – February 2009. The suit, which was filed in the Circuit Court for the Twentieth Judicial District in and for Lee County Florida (the “Court”), seeks, among other items, an accounting of all commissions
which may be due and owing to Ms. Elias and alleges that NeoGenomics owes Ms. Elias approximately $96,000 in unpaid commissions. Ms. Elias abandoned her position in early February and failed to show up for a National Sales Meeting and failed to
return phone calls. The Company terminated her in mid February 2009. In April 2011, the Company produced extensive discovery in this matter, and sought for a dismissal of the case. On March 19, 2012, Counsel for Ms. Elias agreed to dismiss the case
with Prejudice. The Company is currently waiting for formal notice of such dismissal from the court.
  
 Other Litigation in the Normal Course of Business
  

From time to time the Credit Parties are also subject to legal proceedings, claims and litigation arising in the ordinary course of
business where (a) the amount in controversy does not exceed $125,000 and (b) no injunctive relief is being sought by the parties. We do not expect the ultimate costs to resolve these matters to have a material adverse effect on our consolidated
financial position, results of operations or cash flows.

 [***] Information redacted pursuant to a confidential treatment request. An unredacted version of this Agreement has been
filed separately with the Securities and Exchange Commission. 

  
 6 

			
	Schedule 7.8	  	 (Tax Audit)
  

During January 2012, the Internal Revenue Service notified the Company that they were going to conduct an audit of our tax returns for the years ended
December 31, 2010 and 2009, respectively. We are in the preliminary phase of these audits and have no information as to the overall impact of this audit.

		
	Schedule 7.11	  	 Intellectual Property
  

The Company has received a registered trademark for the name “NeoGenomics” for use in the business in which it currently operates and related
businesses. The Company has also trademarked the brand names “MelanoSITE”, “NeoFISH”, “NeoFLOW” and ”DermFISH”.

		
	Schedule 7.15A	  	Existing Indebtedness, Investments, Guarantees and Certain Contracts
		
		  	Existing Indebtedness of Guarantor
		
		  	 Existing Indebtedness and Contracts for Indebtedness by Borrower

 
 As follows:

  
 7 

																													
	 As of February 29th, 2012

 
	 
	Lease
#	  	Ledger Description	  	Asset Description	  	Starting
Balance	 	  	Start
Date	 	  	Term	 	  	 End
 Date
	 	  	Total Pmt	 	  	Trial Balance
2/29/2012	 
	 2
	  	 Lease #2 Balboa
	  	 Furniture and Fixtures
	  	 	18,988.56	  	  	 	May-07	  	  	 	59	  	  	 	Mar-12	  	  	 	440.82	  	  	 	435.94	  
	 5
	  	 Lease #5 Beckman Coulter
	  	 Cytomics PC500
	  	 	136,117.56	  	  	 	Jul-07	  	  	 	60	  	  	 	Jun-12	  	  	 	2,791.77	  	  	 	10,972.41	  
	 18
	  	 Lease #18 Key Equipment
	  	 Genetic Imaging System
	  	 	134,461.00	  	  	 	Aug-07	  	  	 	60	  	  	 	Jul-12	  	  	 	3,089.94	  	  	 	14,883.39	  
	 19
	  	 Lease #19 Great American
	  	 Genetic Imaging System
	  	 	55,661.84	  	  	 	Sep-07	  	  	 	59	  	  	 	Jul-12	  	  	 	1,391.68	  	  	 	6,672.04	  
	 23
	  	 Lease #23 Beckman Coulter
	  	 Laboratory Equipment
	  	 	128,818.83	  	  	 	Dec-07	  	  	 	60	  	  	 	Nov-12	  	  	 	2,642.07	  	  	 	22,959.15	  
	 25
	  	 Lease #25 De Lage Landen
	  	 Laboratory Equipment
	  	 	76,502.14	  	  	 	May-08	  	  	 	58	  	  	 	Feb-13	  	  	 	1,937.86	  	  	 	20,830.00	  
	 29
	  	 Lease #29 Baytree
	  	 Laboratory Equipment
	  	 	82,536.52	  	  	 	Oct-08	  	  	 	58	  	  	 	Jul-13	  	  	 	2,293.46	  	  	 	31,792.81	  
	 34
	  	 Lease #34 Court Square
	  	 Laboratory Equipment
	  	 	35,674.73	  	  	 	Jan-09	  	  	 	58	  	  	 	Oct-13	  	  	 	1,022.32	  	  	 	16,865.29	  
	 36
	  	 Lease #36 Beckman Culter
	  	 Flow Cytometer
	  	 	125,362.20	  	  	 	Jan-09	  	  	 	60	  	  	 	Dec-13	  	  	 	2,705.51	  	  	 	51,983.16	  
	 37
	  	 Lease #37 Credential Leasing
	  	 Computer Hardware
	  	 	63,849.10	  	  	 	Feb-09	  	  	 	46	  	  	 	Nov-12	  	  	 	2,099.86	  	  	 	18,947.69	  
	 39
	  	 Lease #39 VAR Resources
	  	 Computer Hardware
	  	 	60,480.59	  	  	 	Jun-09	  	  	 	34	  	  	 	Mar-12	  	  	 	2,340.06	  	  	 	4,433.58	  
	 40
	  	 Lease #40 LTI
	  	 Laboratory Equipment
	  	 	424,115.57	  	  	 	Jun-09	  	  	 	35	  	  	 	Apr-12	  	  	 	15,357.57	  	  	 	44,805.75	  
	 41
	  	 Lease #41 LTI
	  	 Laboratory Equipment
	  	 	38,613.77	  	  	 	Jul-09	  	  	 	35	  	  	 	May-12	  	  	 	1,424.63	  	  	 	5,491.95	  
	 42
	  	 Lease #42 Butler Capital
	  	 Furniture and Fixtures
	  	 	95,002.07	  	  	 	Sep-09	  	  	 	35	  	  	 	Jul-12	  	  	 	3,305.62	  	  	 	19,067.47	  
	 43
	  	 Lease #43 Beckman Culter
	  	 Flow Cytometer
	  	 	125,580.80	  	  	 	Sep-09	  	  	 	60	  	  	 	Aug-14	  	  	 	2,710.24	  	  	 	73,144.14	  
	 44
	  	 Lease #44 Royal Bank America
	  	 Computer Hardware
	  	 	84,346.75	  	  	 	Sep-09	  	  	 	36	  	  	 	Aug-12	  	  	 	3,082.36	  	  	 	20,286.98	  
	 45
	  	 Lease #45 LTI
	  	 Furniture and Fixtures
	  	 	28,177.44	  	  	 	Sep-09	  	  	 	35	  	  	 	Jul-12	  	  	 	1,013.36	  	  	 	5,805.48	  
	 46
	  	 Lease #46 Wells Fargo
	  	 Laboratory Equipment
	  	 	282,896.60	  	  	 	Oct-09	  	  	 	60	  	  	 	Sep-14	  	  	 	5,767.57	  	  	 	160,568.88	  
	 47
	  	 Lease #47 Suntrust
	  	 Lab Equip, Furn, Comp HDW
	  	 	422,904.72	  	  	 	Nov-09	  	  	 	59	  	  	 	Sep-14	  	  	 	8,433.67	  	  	 	246,503.29	  
	 48
	  	 Lease #48 Wells Fargo
	  	 Laboratory Equipment
	  	 	421,516.02	  	  	 	Jan-10	  	  	 	60	  	  	 	Dec-14	  	  	 	8,627.66	  	  	 	266,999.49	  
	 49
	  	 Lease #49 Suntrust
	  	 Lab Equip, Furn, Comp HDW
	  	 	287,992.18	  	  	 	Jan-10	  	  	 	59	  	  	 	Nov-14	  	  	 	5,703.88	  	  	 	176,906.05	  
	 50
	  	 Lease #50 De Lage Landen
	  	 Copiers
	  	 	30,138.78	  	  	 	Mar-10	  	  	 	34	  	  	 	Dec-12	  	  	 	1,085.91	  	  	 	11,123.67	  
	 51
	  	 Lease #51 Suntrust
	  	 Lab Equip, Furn, Comp HDW
	  	 	246,537.47	  	  	 	Apr-10	  	  	 	59	  	  	 	Feb-15	  	  	 	4,903.31	  	  	 	163,775.11	  
	 52
	  	 Lease #52 VAR Resources
	  	 Software, Computer
	  	 	22,778.55	  	  	 	Jun-10	  	  	 	23	  	  	 	Apr-12	  	  	 	1,235.49	  	  	 	2,401.33	  
	 53
	  	 Lease #53 Butler Capital
	  	 Laboratory Equipment
	  	 	47,312.47	  	  	 	Jun-10	  	  	 	34	  	  	 	Mar-13	  	  	 	1,701.17	  	  	 	21,813.22	  
	 54
	  	 Lease #54 HP
	  	 Computer Hardware
	  	 	15,326.72	  	  	 	Jul-10	  	  	 	35	  	  	 	May-13	  	  	 	533.37	  	  	 	7,316.70	  
	 55
	  	 Lease #55 Verizon Credit
	  	 Computer Hardware
	  	 	25,972.85	  	  	 	Sep-10	  	  	 	59	  	  	 	Jul-15	  	  	 	488.03	  	  	 	18,608.80	  
	 56
	  	 Lease #56 Butler Capital
	  	 Laboratory Equipment
	  	 	57,671.98	  	  	 	Oct-10	  	  	 	34	  	  	 	Jul-13	  	  	 	2,354.34	  	  	 	32,323.05	  
	 57
	  	 Lease #57 Key Equipment
	  	 Laboratory Equipment
	  	 	64,458.34	  	  	 	Oct-10	  	  	 	34	  	  	 	Jul-13	  	  	 	2,620.83	  	  	 	37,536.67	  
	 58
	  	 Lease #58 LTI
	  	 Laboratory Equipment
	  	 	44,817.91	  	  	 	Oct-10	  	  	 	35	  	  	 	Aug-13	  	  	 	1,638.88	  	  	 	25,826.90	  
	 59
	  	 Lease #59 LTI
	  	 Computer Hardware
	  	 	87,199.57	  	  	 	Oct-10	  	  	 	35	  	  	 	Aug-13	  	  	 	3,154.39	  	  	 	50,006.23	  
	 60
	  	 Lease #60 HP
	  	 Computer Hardware
	  	 	17,204.26	  	  	 	Nov-10	  	  	 	35	  	  	 	Sep-13	  	  	 	634.32	  	  	 	10,429.88	  
	 61
	  	 Lease #61 LTI
	  	 Laboratory Equipment
	  	 	30,151.63	  	  	 	Dec-10	  	  	 	35	  	  	 	Oct-13	  	  	 	1,088.62	  	  	 	19,768.40	  
	 62
	  	 Lease #62 VAR Resources
	  	 Computer Hardware
	  	 	12,595.85	  	  	 	Dec-10	  	  	 	34	  	  	 	Sep-13	  	  	 	489.01	  	  	 	8,251.70	  
	 63
	  	 Lease #63 LTI
	  	 Laboratory Equipment
	  	 	159,789.42	  	  	 	Dec-10	  	  	 	35	  	  	 	Oct-13	  	  	 	5,750.50	  	  	 	104,638.15	  
	 64
	  	 Lease #64 LTI
	  	 Laboratory Equipment
	  	 	35,573.04	  	  	 	Dec-10	  	  	 	35	  	  	 	Oct-13	  	  	 	1,311.40	  	  	 	23,501.93	  
	 65
	  	 Lease #65 VAR Resources
	  	 Computer Hardware
	  	 	21,174.04	  	  	 	Dec-10	  	  	 	34	  	  	 	Sep-13	  	  	 	817.05	  	  	 	13,839.73	  
	 66
	  	 Lease #66 VAR Resources
	  	 Computer Hardware
	  	 	13,349.34	  	  	 	Apr-11	  	  	 	34	  	  	 	Jan-14	  	  	 	537.32	  	  	 	10,268.71	  
	 67
	  	 Lease #67 LTI
	  	 Laboratory Equipment
	  	 	14,045.00	  	  	 	Apr-11	  	  	 	35	  	  	 	Feb-14	  	  	 	507.51	  	  	 	10,687.15	  
	 68
	  	 Lease #68 LTI
	  	 Laboratory Equipment
	  	 	69,572.26	  	  	 	Apr-11	  	  	 	35	  	  	 	Feb-14	  	  	 	2,557.80	  	  	 	53,177.11	  
	 69
	  	 Lease #69 LTI
	  	 Generator
	  	 	37,628.00	  	  	 	Apr-11	  	  	 	35	  	  	 	Feb-14	  	  	 	1,383.30	  	  	 	28,760.28	  
	 70
	  	 Lease #70 VAR Resources
	  	 Computer Hardware
	  	 	8,774.84	  	  	 	Apr-11	  	  	 	34	  	  	 	Jan-14	  	  	 	353.34	  	  	 	6,750.60	  
	 71
	  	 Lease #71 First Sound
	  	 Computer Hardware
	  	 	13,841.20	  	  	 	Aug-11	  	  	 	34	  	  	 	May-14	  	  	 	545.41	  	  	 	11,958.19	  
	 72
	  	 Lease #72 LTI
	  	 Laboratory Equipment
	  	 	156,458.44	  	  	 	Jun-11	  	  	 	35	  	  	 	Apr-14	  	  	 	5,619.06	  	  	 	134,499.09	  
	 73
	  	 Lease #73 LTI
	  	 Laboratory Equipment
	  	 	156,286.16	  	  	 	Jun-11	  	  	 	35	  	  	 	Apr-14	  	  	 	5,791.34	  	  	 	135,000.12	  
	 74
	  	 Lease #74 First Sound
	  	 Computer Hardware
	  	 	9,448.63	  	  	 	Jul-11	  	  	 	34	  	  	 	Apr-14	  	  	 	379.07	  	  	 	7,732.61	  
	 75
	  	 Lease #75 LTI
	  	 Laboratory Equipment
	  	 	17,359.46	  	  	 	Sep-11	  	  	 	35	  	  	 	Jul-14	  	  	 	640.54	  	  	 	15,377.69	  
	 76
	  	 Lease #76 First Sound
	  	 Computer Hardware
	  	 	10,486.81	  	  	 	Sep-11	  	  	 	34	  	  	 	Jun-14	  	  	 	405.96	  	  	 	9,287.08	  
	 77
	  	 Lease #77 LTI
	  	 Laboratory Equipment
	  	 	41,243.50	  	  	 	Sep-11	  	  	 	35	  	  	 	Jul-14	  	  	 	1,480.82	  	  	 	36,450.48	  
	 78
	  	 Lease #78 LTI
	  	 Laboratory Equipment
	  	 	270,707.68	  	  	 	Sep-11	  	  	 	35	  	  	 	Jul-14	  	  	 	9,722.32	  	  	 	239,256.69	  
	 79
	  	 Lease #79 LTI
	  	 Laboratory Equipment
	  	 	307,228.52	  	  	 	Sep-11	  	  	 	35	  	  	 	Jul-14	  	  	 	11,092.63	  	  	 	271,719.84	  
	 80
	  	 Lease #80 Key Equipment
	  	 Computer Hardware
	  	 	59,867.70	  	  	 	Sep-11	  	  	 	36	  	  	 	Aug-14	  	  	 	2,226.96	  	  	 	52,198.53	  
	 81
	  	 Lease #81 De Lage Landen
	  	 Furniture and Fixtures
	  	 	31,046.76	  	  	 	Sep-11	  	  	 	59	  	  	 	Jul-16	  	  	 	820.94	  	  	 	29,742.59	  
	 82
	  	 Lease #82 Baytree
	  	 Laboratory Equipment
	  	 	59,694.32	  	  	 	Sep-11	  	  	 	46	  	  	 	Jun-15	  	  	 	1,954.93	  	  	 	56,298.12	  
	 83
	  	 Lease #83 Beckman Culter
	  	 Laboratory Equipment
	  	 	378,637.66	  	  	 	Oct-11	  	  	 	60	  	  	 	Sep-16	  	  	 	7,712.85	  	  	 	363,151.47	  

  
 8 

																													
	 84
	  	 Lease #84 VAR Resources
	  	 Computer Hardware
	  	 	12,333.96	  	  	 	Nov-11	  	  	 	34	  	  	 	Aug-14	  	  	 	495.91	  	  	 	11,534.87	  
	 85
	  	 Lease #85 VAR Resources
	  	 Computer Hardware
	  	 	11,854.18	  	  	 	Nov-11	  	  	 	34	  	  	 	Aug-14	  	  	 	477.37	  	  	 	11,087.51	  
	 86
	  	 Lease #86 LTI
	  	 Laboratory Equipment
	  	 	43,434.51	  	  	 	Nov-11	  	  	 	35	  	  	 	Sep-14	  	  	 	1,577.73	  	  	 	40,482.02	  
	 87
	  	 Lease #87 LTI
	  	 Laboratory Equipment
	  	 	290,485.54	  	  	 	Nov-11	  	  	 	35	  	  	 	Sep-14	  	  	 	10,431.46	  	  	 	270,501.80	  
	 88
	  	 Lease #88 De Lage Landen
	  	 Furniture and Fixtures
	  	 	34,733.97	  	  	 	Nov-11	  	  	 	59	  	  	 	Sep-16	  	  	 	943.39	  	  	 	33,685.56	  
	 89
	  	 Lease #89 Garic
	  	 Laboratory Equipment
	  	 	45,597.66	  	  	 	Nov-11	  	  	 	36	  	  	 	Oct-14	  	  	 	1,609.44	  	  	 	42,584.91	  
	 90
	  	 Lease #90 Garic
	  	 Laboratory Equipment
	  	 	55,862.52	  	  	 	Nov-11	  	  	 	36	  	  	 	Oct-14	  	  	 	1,945.26	  	  	 	52,118.89	  
	 91
	  	 Lease #91 DDI
	  	 Computer Hardware
	  	 	85,100.00	  	  	 	Nov-11	  	  	 	36	  	  	 	Oct-14	  	  	 	3,107.39	  	  	 	79,676.76	  
	 92
	  	 Lease #92 Conestoga
	  	 Computer Hardware
	  	 	64,468.86	  	  	 	Nov-11	  	  	 	36	  	  	 	Oct-14	  	  	 	2,444.60	  	  	 	60,282.60	  
	 93
	  	 Lease #93 Garic
	  	 Laboratory Equipment
	  	 	97,988.38	  	  	 	Nov-11	  	  	 	36	  	  	 	Oct-14	  	  	 	3,366.06	  	  	 	93,574.83	  
	 94
	  	 Lease #94 Dell
	  	 Computer Hardware
	  	 	371,968.12	  	  	 	Dec-11	  	  	 	60	  	  	 	Nov-16	  	  	 	7,167.12	  	  	 	361,241.09	  
	 95
	  	 Lease #95 VAR Resources
	  	 Software, Computer
	  	 	54,432.99	  	  	 	Jan-12	  	  	 	34	  	  	 	Oct-14	  	  	 	1,967.80	  	  	 	51,817.46	  
	 96
	  	 Lease #96 Garic Sch#5
	  	 Laboratory Equipment
	  	 	49,365.84	  	  	 	Jan-12	  	  	 	36	  	  	 	Dec-14	  	  	 	1,684.72	  	  	 	48,185.43	  
	 97
	  	 Lease #97 Garic Sch#6
	  	 Computer Hardware
	  	 	38,886.55	  	  	 	Jan-12	  	  	 	36	  	  	 	Dec-14	  	  	 	1,270.37	  	  	 	37,913.19	  
	 98
	  	 Lease #98 Garic Sch#4
	  	 Laboratory Equipment
	  	 	88,697.57	  	  	 	Jan-12	  	  	 	36	  	  	 	Dec-14	  	  	 	3,032.54	  	  	 	86,580.80	  
	 99
	  	 Lease #99 Garic Sch#7
	  	 Laboratory Equipment
	  	 	47,658.24	  	  	 	Feb-12	  	  	 	36	  	  	 	Jan-15	  	  	 	1,655.94	  	  	 	47,658.24	  
	 100
	  	 Lease #100 Royal Bank
	  	 Laboratory Equipment
	  	 	47,559.32	  	  	 	Feb-12	  	  	 	34	  	  	 	Nov-14	  	  	 	1,879.99	  	  	 	47,559.32	  
	 101
	  	 Lease #101 VAR
	  	 Computer Hardware
	  	 	19,242.29	  	  	 	Feb-12	  	  	 	34	  	  	 	Nov-14	  	  	 	698.44	  	  	 	19,242.29	  
									
		  		  		  	 	7,163,648.65	  	  				  				  				  	 	207,476.16	  	  	 	4,639,560.33	  
								
	Car Loans	  	 	  	 	 	  	 	 	  	 	 	  	 	 	  	 	 	  	 	 
									
	 1
	  	 2011 Hyundai Accent
	  		  	 	15,179.86	  	  	 	Apr-10	  	  	 	36	  	  	 	Mar-13	  	  	 	469.28	  	  			
	 2
	  	 2011 Hyundai Accent
	  		  	 	15,179.86	  	  	 	Apr-10	  	  	 	36	  	  	 	Mar-13	  	  	 	469.28	  	  			
	 3
	  	 2011 Hyundai Accent
	  		  	 	16,539.11	  	  	 	Jul-11	  	  	 	36	  	  	 	Jun-14	  	  	 	506.25	  	  			
	 4
	  	 2011 Hyundai Accent
	  		  	 	16,539.11	  	  	 	Jul-11	  	  	 	36	  	  	 	Jun-14	  	  	 	506.25	  	  			
	 5
	  	 2012 Kia Sedona
	  		  	 	23,014.31	  	  	 	Dec-11	  	  	 	36	  	  	 	Nov-14	  	  	 	742.22	  	  			
	 6
	  	 2012 Kia Sedona
	  		  	 	23,014.31	  	  	 	Dec-11	  	  	 	36	  	  	 	Nov-14	  	  	 	742.22	  	  			
	 7
	  	 2012 Chevrolet Express
	  		  	 	28,807.80	  	  	 	Dec-11	  	  	 	36	  	  	 	Nov-14	  	  	 	863.86	  	  			
									
		  		  		  	 	138,274.36	  	  				  				  				  	 	4,299.36	  	  	 	110,843.27	  
								
	 TOTAL INDEBTEDNESS
	  		  	 	7,301,923.01	  	  				  				  				  	 	211,775.52	  	  	 	4,750,403.60	  

  

			
	Schedule 7.15A	  	Existing Indebtedness, Investments, Guarantees and Certain Contracts
		
		  	Existing Indebtedness of Guarantor
		
		  	 Investments Held by Guarantor
  

Exclusive License Agreement with Health Discovery Corporation for certain patents and pending patents, valued at approximately
$2,950,000 as of January 6, 2012.
  
 Certain pending
patents relating to the detection of neurodegenerative diseases and breast cancer formerly owned by Power3 Medical Products, Inc.

		
		  	 Investments Held by Subsidiary
  

None

		
	Schedule 7.15B	  	 Indebtedness with a Maturity Date During the Term
  

See Schedule 7.15A

		
	Schedule 7.16	  	Other Agreements - See Schedule 7.5
		
	Schedule 7.17	  	 Insurance
  

As follows:

  
 9 

																							
	NeoGenomics Laboratories, Inc.	 
	 Commercial Insurance Schedule

 
	 
	 	  	Broker/Agent	  	Carrier (Ins. Co)	  	Policy Number	  	Policy
Premium	 	  	Effective
Date	 	  	Expiration
Date	 	  	Limit	 
		  		  	Homeland	  		  				  				  				  			
		  		  	Insurance	  		  				  				  				  			
		  		  	Company of NY	  		  				  				  				  			
	1	  	Russell Bond & Co.	  	(Prof Liab)	  	MFL085111	  	$	68,500	  	  	 	10/9/2011	  	  	 	10/9/2012	  	  	$	1M/$3M	  
								
		  		  	Homeland	  		  				  				  				  	$	10M Excess on	  
	2	  	Russell Bond & Co.	  	Insurance	  	MFL085111	  	$	35,734	  	  	 	10/9/2011	  	  	 	10/9/2012	  	  	 	all Underlying	  
								
		  		  	Amerisure	  		  				  				  				  			
	3	  	Gulfshore Insurance	  	Automobile	  	CA 20532130602	  	$	4,849	  	  	 	5/4/2011	  	  	 	5/4/2012	  	  	 	See Policy	  
		  		  	Amerisure Commercial	  	CPP20532140400 11	  	$	69,618	  	  	 	5/4/2011	  	  	 	5/4/2012	  	  	 	See Policy	  
		  		  	Amerisure	  		  				  				  				  			
		  		  	General Liability	  	GL20532150502	  	$	11,325	  	  	 	5/4/2011	  	  	 	5/4/2012	  	  	$	1M/$2M	  
		  		  	Umbrella	  	CU20532160401	  	$	7,083	  	  	 	5/4/2011	  	  	 	5/4/2012	  	  	UL $	4M	  
								
		  		  	Amerisure	  		  				  				  				  			
		  		  	Worker’s	  		  				  				  				  			
	4	  	Gulfshore Insurance	  	Compensation	  	WC205387903	  	$	87,632	  	  	 	5/4/2011	  	  	 	5/4/2012	  	  	 	See Policy	  
								
		  		  	Risk Insurance	  		  				  				  				  			
		  		  	Brokers of the	  		  				  				  				  			
	5	  	Gulfshore	  	West Earthquake	  	XCH500808701	  	$	30,600	  	  	 	11/6/2011	  	  	 	11/6/2012	  	  	$	4.4M	  
								
		  		  	Great American	  		  				  				  				  			
		  		  	Insurance	  		  				  				  				  			
	6	  	Russell Bond	  	Company D&O	  	NSP2380654	  	$	35,200	  	  	 	6/15/2011	  	  	 	6/15/2012	  	  	$	5M	  
		  		  	Great American	  		  				  				  				  			
		  		  	Insurance	  		  				  				  				  			
		  		  	Company $5M xs	  		  				  				  				  			
	6a	  	Russell Bond	  	$5M D&O	  	DOX0039306-01	  	$	26,000	  	  	 	6/15/2011	  	  	 	6/15/2012	  	  	$	5M xs of $5M	  
								
		  		  	Great Amercian	  		  				  				  				  			
	7	  	Russell Bond	  	EPL	  	EPL2824392	  	$	8,124	  	  	 	6/15/2011	  	  	 	6/15/2012	  	  	$	1M	  
								
		  		  	Great American	  		  				  				  				  			
	8	  	Russell Bond	  	Fidiciary Liability	  	FDP6660848	  	$	800	  	  	 	6/15/2011	  	  	 	6/15/2012	  	  	$	1M	  
								
		  		  	International	  		  				  				  				  			
		  		  	Fidelity Insurance	  		  				  				  				  			
		  		  	Company	  		  				  				  				  			
		  		  	Medicaid Provider	  		  				  				  				  			
	9	  	Bacarella Insurance	  	Surety Bond	  		  	$	1,500	  	  	 	2/25/2012	  	  	 	2/25/2013	  	  	$	50,000	  

  
 10 

			
	Schedule 7.18A	  	 Borrower’s Names
  

NeoGenomics Laboratories, Inc.
 NeoGenomics Laboratories

		
	Schedule 7.18B	  	 Chief Executive Offices and Other Places of Business

 
 Chief Executive Offices

12701 Commonwealth Drive, Suites 1-9
 Fort Myers, FL 33913
  
 Other Places of Business
 618 Grassmere Park Drive, Suite
20
 Nashville, TN 37211
  

6 Morgan Street, Suite’s 116, 130 and 150
 Irvine, CA 92618
  
 10002 Princess Palm Avenue, Suite 228
 Tampa, FL 33619

		
	Schedule 8.8	  	Post-Closing Matters
		
	Schedule 9.2	  	 Permitted Indebtedness
  

All Capital Leases listed in Schedule 7.15A

		
	Schedule 9.3	  	 Permitted Liens
  

Purchase Money on all Equipment financed through the Capital Leases listed on Schedule 7.15A

		
	Schedule 9.5	  	 Related Party Contracts
  

All Related Party agreements listed in Schedule 7.5

  
 11

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00203-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00203-of-00352.parquet"}]]